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ABSTRACT:
Obesity is associated with low-grade inflammation and extracellular matrix (ECM)
remodeling, both of which also contribute to adipose tissue dysfunction. Obesity is a major
risk factor for the development of type 2 diabetes and cardiovascular diseases. Previous
studies by our group have demonstrated that weight reduction changes the gene
expression profile of white adipose tissue (wAT) in overweight subjects with features of
metabolic syndrome. Among the down-regulated genes in response to weight loss were
microfibrillar-associated protein 5 (MFAP5) and a calcineurin-like phosphoesterase domain
containing 1 (CPPED1).
Previous studies on MFAP5 demonstrate that it is involved in elastinogenesis, cell
survival and angiogenesis, but the function of CPPED1 is unknown. The overall aim of this
thesis work was to investigate whether changes in gene expressions of MFAP5 and CPPED1
were associated with changes in wAT biology in obesity and to elucidate the possible roles
of MFAP5 and CPPED1 in controlling adipocyte function, inflammation and glucose
metabolism at cellular level in cultured adipocytes.
MFAP5 expression was correlated with factors related to ECM remodeling and
inflammation in wAT samples. Modified expression of MFAP5 by  down-regulation  in
cultured adipocytes decreased the expression of ECM components and inflammatory
genes. Furthermore, inflammatory factors increased the expression of MFAP5 in
preadipocytes. CPPED1 expression  was  positively  correlated  with  the  expression  of
inflammatory  genes  in  wAT  and  peripheral  blood  mononuclear  cells  (PBMCs),  and  the
expression of CPPED1 tended to increase in response to tumour necrosis factor alpha
(TNF) treatment in cultured adipocytes. Decreased expression of CPPED1 enhanced
insulin-stimulated glucose uptake, possibly through a phosphatidyl inositol 3-kinase (PI3K)
-dependent pathway, and adiponectin signaling pathway could either directly or indirectly
play a role in this regulation.
In conclusion, the present results demonstrate that MFAP5 and CPPED1 have a role in
wAT biology and could contribute to complications in dysfunctional wAT, which could be
in  part  reversed  by  weight  reduction.  Furthermore,  the  results  suggest  that MFAP5 is
involved in ECM function and wAT inflammation. Reduction in CPPED1 expression
enhances insulin-stimulated glucose uptake, possibly via adiponectin-mediated
mechanisms.
National Library of Medicine Classification: QS 532.5.A3, QU 55.3, QU 350, QU 475, WD 210
Medical  Subject  Headings:  Obesity/genetics;  Weight  Loss/genetics;  Adipocytes;  Adipose  Tissue,  White;
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TIIVISTELMÄ:
Lihavuus on yhteydessä matala-asteiseen tulehdustilaan ja sidekudoksen muokkaukseen.
Molemmat myös vaikuttavat rasvakudoksen toimintahäiriöön. Lihavuus on myös
merkittävä riskitekijä tyypin 2 diabeteksen ja sydän- ja verisuonitautien kehittymiselle.
Tutkimusryhmämme aikaisemmat tutkimukset ovat osoittaneet, että laihduttaminen voi
muuttaa valkoisessa rasvakudoksessa ilmentyvien geenien profiilia ylipainoisilla
henkilöillä, joilla on metabolisen oireyhtymän piirteitä. MFAP5 (microfibrillar-associated
protein 5) ja CPPED1 (calcineurin-like phosphoesterase domain containing 1) olivat niiden
geenien joukossa, joiden ilmentyminen väheni laihdutuksen myötä.
Aikaisemmat tutkimukset MFAP5:stä osoittavat sen olevan yhteydessä
elastinogeneesiin, verisuonten uudismuodostukseen ja solujen eloonjäämiseen, mutta
CPPED1:n toiminto on kuitenkin tuntematon. Tämän väitöskirjatyön kokonaistavoite oli
tutkia ovatko MFAP5- ja CPPED1-geenien ilmentymisen muutokset yhteydessä muutoksiin
lihavuuden valkoisen rasvakudoksen biologiaan, ja selventää MFAP5:n ja CPPED1:n
mahdollisia tehtäviä rasvasolun toiminnassa, tulehdustilassa ja
glukoosiaineenvaihdunnassa solutasolla rasvasoluviljelmässä.
Rasvakudosnäytteissä MFAP5 ilmentyminen  korreloi  sidekudoksen  muokkaukseen  ja
tulehdustilaan liittyvien tekijöiden kanssa. MFAP5:n ilmentymisen vähentäminen
rasvasoluviljelmässä vähensi sidekudoskomponenttien ja tulehdukseen liittyvien geenien
ilmentymistä. Lisäksi tulehdustekijät lisäsivät MFAP5:n ilmentymistä rasvasolun
esiastesoluissa, preadiposyyteissä. Valkoisessa rasvakudoksessa ja perifeerisen veren
mononukleaarisoluissa CPPED1 ilmentyminen korreloi positiivisesti tulehdustilaan
liittyvien geenien ilmentymisen kanssa ja tuumorinekroositekijä alfa (TNF) -altistuksella
oli taipumus lisätä sen ilmentymistä rasvasoluviljelmässä. Vähentynyt CPPED1:n
ilmentyminen lisäsi insuliinilla stimuloitua glukoosin sisäänottoa soluun mahdollisesti
fosfatidyyli-inositoli 3 kinaasi (PI3K) -riippuvaisen signaalitien kautta ja adiponektiinin
signalointireitillä saattaa olla rooli tässä säätelyssä, joko suorasti tai epäsuorasti.
Yhteenvetona tulokset näyttävät, että MFAP5:llä ja CPPED1:llä on rooli valkoisen
rasvakudoksen biologiassa ja ne saattavat vaikuttaa valkoisen rasvakudoksen
toimintahäiriöihin, jotka osittain voidaan korjata laihduttamisella. Tulokset osoittavat
myös, että MFAP5 on yhteydessä sidekudoksen toimintaan ja valkoisen rasvakudoksen
tulehdustilaan, kun taas CPPED1 ilmentymisen vähentyminen tehostaa insuliinilla
stimuloitua glukoosin sisäänottoa soluun, mahdollisesti adiponektiinivälitteisten
mekanismien kautta.
Luokitus: QS 532.5.A3, QU 55.3, QU 350, QU 475, WD 210
Yleinen Suomalainen asiasanasto: lihavuus; rasvakudokset; sidekudokset; geenit; geeniekspressio; glukoosi;
insuliini; insuliiniresistenssi; tulehdus; soluviljely
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1 Introduction
During the last decades, obesity has been considered a major public health problem (1)
and is associated with an increased incidence and prevalence of obesity-related co-
morbidities, such as insulin resistance (IR), type 2 diabetes, hypertension, cardiovascular
diseases and several types of cancer (2-4). The burden related to obesity and its co-
morbidities has increased the basic and applied research on the role of white adipose
tissue (wAT) in regulating physiological and pathological processes (5).
WAT is a highly active metabolic and endocrine organ. It is one of the key tissues
having an effect on human energy metabolism and inflammation, thus, having also a
major  role  in  the  development  of  metabolic  abnormalities  in  obesity  (6).  Enlargement  of
wAT is associated with adipocyte hypertrophy followed by increased low-grade
inflammation, abnormal production of adipokines, immune cell infiltration into wAT and
the extracellular matrix (ECM) remodeling (7-11), finally leading to dysfunctional wAT
(12).
The ECM maintains the integrity of wAT and is composed of collagens, glycoproteins
and proteoglycans (13-15). In obesity, the synthesis of ECM components is increased,
potentially leading to fibrosis which links obesity to diabetes and cardiovascular diseases
in association with inflammation (11,16).
Lifestyle  modification  aiming  at  weight  reduction  has  been  shown  to  prevent  many
obesity associated co-morbidities and to reduce the risk of type 2 diabetes via improving
insulin and glucose metabolism and attenuating the low-grade chronic inflammatory state
(17-19). Furthermore, ECM remodeling could be reversed by weight loss. Changes in gene
expression of ECM during weight gain and losss suggest a role of ECM in wAT biology in
obesity (9).
The strategy of our research group has been to identify new putative genes related to
obesity and type 2 diabetes. Alterations in body weight have multitude of changes in wAT
gene expression. In a previous study of our group, microfibrillar-associated protein 5
(MFAP5) and a calcineurin-like phosphoesterase domain containing 1 (CPPED1) were
down-regulated during weight reduction in overweight subjects with impaired fasting
glucose or impaired glucose tolerance, supporting them as putative genes involved in
wAT biology, obesity and its related conditions (20).
The purpose of this thesis work was to investigate the possible roles of MFAP5 and
CPPED1 in controlling adipocyte function, inflammation and glucose metabolism at the
cellular  level  using  human  peripheral  tissues  and  adipocyte  cell  culture  models.
Specifically, 1) the relationship between the expression of target genes and changes in
adiposity, glucose metabolism and inflammation, 2) the functions of target genes by gene
silencing technology on adipocyte function and glucose metabolism in adipocyte cell
cultures and 3) the effect of inflammatory cytokines on the expression of target genes in
adipocyte cell cultures were studied.
22 Review of literature
2.1 OBESITY
During positive energy balance wAT stores excess of lipids as triglycerides which leads to
wAT enlargement and development of obesity (21), which increases the risk for type 2
diabetes and cardiovascular diseases (22). Traditionally, body mass index (BMI) is used as
a common indicator to measure body fat and to diagnose underweight and overweight
(23). Overweight is defined as BMI (calculated dividing weight by height in meters
squared)  25 kg/m2 and obesity as BMI  30 kg/m2 (24,25).
However,  the  distribution  of  fat  differs  in  obesity  (24),  and  BMI  does  not  account  for
this variation. That is, BMI does not differentiate the weight between muscle and fat
tissues or location of wAT (24). Therefore, other measures, such as waist circumference
and waist-to-hip ratio, which are more closely associated with the risk of cardiovascular
diseases than BMI, more accurately describe fat distribution (26,27). Specifically,
abdominal or central obesity has been shown to be associated with adipocyte hypertrophy
and development of IR and its complications like type 2 diabetes, hypertension and
cardiovascular diseases (28-30). In contrast, peripheral obesity is associated with less
metabolic risk (31). There are also regional differences in fat distribution between males
and females. Abdominal (upper-body) obesity is more frequent in males, whereas
peripheral obesity in gluteal and femoral regions (lower-body) is more common in females
(32).  There  is  a  great  interest  towards  identifying  the  main  factors  contributing  to  the
development of obesity which results from the interaction of lifestyle (unhealthy diet and
low physical activity) and genetic factors (21,30,33,34).
The increasing prevalence of obesity is widely documented (24). According to World
Health Organization (35) in 2008, 34% of men and 35% of women were overweight, and
10% of men and 14% of women were classified as obese (35). These numbers are in line
with the situation in Finland. In Finland, the prevalence of obesity has increased during
the last decades (36). Based on the FinRisk 2012 study, 66% of men and 46% of women
were classified as overweight (BMI  25 kg/m2) and 20% of Finnish people were obese (37).
2.1.1 Obesity-related metabolic changes in white adipose tissue
Enlargement of wAT is associated with increased fat cell volume and recruitment of new
fat cells termed as hypertrophy and hyperplasia, and is followed by increased
angiogenesis, immune cell infiltration into wAT, and ECM overproduction, also termed
wAT remodeling (9,11,38). The increase in wAT mass can have several effects, including
hypoxia, endoplasmic reticulum stress, adipocyte cell death, enhanced adipokine secretion
and dysregulation in fatty acid fluxes (11,39). These processes are a result of dysregulation
of the regulatory system in wAT (21,40,41).
Moreover, obesity is considered as a chronic low-grade inflammatory state (42) with
abnormal production of adipokines such as adiponectin, leptin, tumour necrosis factor
alpha (TNF) and interleukin (IL)-6 from wAT (7,8), which results in disturbed insulin
3sensitivity and impaired glucose metabolism (12). The source of these adipokines is not
completely clear. However, adipocytes and immune cells such as macrophages, which
infiltrate into wAT (43), contribute to the secretion of these adipokines from obese wAT
(4,30,44). Low-grade inflammation is nowadays regarded as a mediating factor between
obesity  and  its  co-morbidities  (45).  In  contrast,  weight  loss  has  been  shown  to  be  an
effective way to improve insulin sensitivity and glucose metabolism (46,47) and reverse
the state of inflammation (18).
2.2 WHITE ADIPOSE TISSUE AS AN ENDOCRINE ORGAN
The discovery of leptin (48), and later adiponectin (49,50), changed our view of wAT as
only serving for energy storage. Nowadays, wAT is also considered to be an endocrine
organ that produces a variety of hormones and bioactive proteins, termed adipokines or
adipocytokines (Table 1), which act in an autocrine, paracrine, or endocrine manner (8,51).
These bioactive molecules regulate biological processes like energy homeostasis, adipocyte
proliferation and differentiation, blood pressure, lipid and glucose metabolism,
angiogenesis and inflammation, thus affecting the metabolism of many organs (13,51,52).
The hormones secreted by major adipocytes, such as adiponectin and leptin, are
considered true adipokines (53) whereas other bioactive proteins, like TNF and IL1,
which are secreted by adipocytes and other cell types in the wAT, are usually called
adipocytokines (54). Table 1 presents key adipokines and adipocytokines associated with
glucose metabolism and obesity-related inflammation in wAT.
Table 1. Key adipokines and adipocytokines secreted from wAT, modified from (13,54)
Secreted factors Change in
obesity
Effects on
Leptin  food intake, glucose metabolism
Adiponectin  insulin sensitivity, fatty acid
oxidation, inflammation
Omentin  insulin sensitivity
Tumour necrosis
factor 
 insulin resistance, adipogenesis,
apoptosis
Interleukin   insulin resistance, inflammation
Interleukin 6  insulin resistance, inflammation
Monocyte
chemoattractant
protein 1
 macrophage infiltration
Resistin  weight regulation, insulin resistance,
inflammation
Visfatin  weight regulation, insulin secretion,
insulin resistance
Plasminogen
activator
inhibitor 1
 fibrinolysis
WAT also produces adipocytokines like TNF, IL1 and IL-6, and other factors like
monocyte chemoattractant protein (MCP) -1, resistin and plasminogen activator inhibitor
(PAI-1), which have also been shown to originate from other cell types in the stromal-
vascular fraction (SVF), such as immune cells (8,30,44,54). WAT also secretes many other
hormones, e.g. omentin and visfatin, but their roles in glucose metabolism in humans need
to be further elucidated (26). The function of these adipokines and adipocytokines is
4important for cross-talk with other organs (40). In obesity the secretion and expression of
adipokines and adipocytokines is dysregulated and contributes to the development of
metabolic abnormalities and the risk of cardiovascular diseases (51,52).
2.2.1 Factors involved in white adipose tissue biology
Leptin levels are increased in obesity (Figure 1) and correlate directly with wAT mass
(5,53). The main function of leptin is to control appetite and energy homeostasis (8). In
addition, leptin is also involved in the inflammatory response, regulation of glucose
homeostasis and insulin sensitivity, hematopoiesis, angiogenesis, bone development and
carcinogenesis (5,8,13,55).
Figure 1. Factors involved in dysregulation of wAT in obesity.
The level of adiponectin is reduced in obesity, IR and type 2 diabetes, and is inversely
correlated to adiposity. Adiponectin levels are increased by weight reduction and
improved insulin sensitivity (3,56). Adiponectin is involved in the regulation of insulin
sensitivity, inhibition of gluconeogenesis and enhancement of fatty acid oxidation in liver,
skeletal muscle and in wAT (57,58). In addition, adiponectin has been demonstrated to
have anti-inflammatory properties via down-regulation of the inflammatory factors TNF
and IL-6 through inhibition of NF-B activation and induction of the anti-inflammatory
factors IL-10 and interleukin 1 receptor antagonist IL1Ra (5). There are several isoforms of
adiponectin circulating in the blood, including full-length or high-molecular weight
(HMW), medium-molecular weight and low-molecular weight adiponectin isoforms. Of
these, particularly the HMW isoform, which is proposed to be the biologically active form,
5has been shown to be negatively associated with IR, metabolic syndrome and
cardiovascular disease (13,59).
The production of TNF, IL-6, IL1 and the anti-inflammatory IL1Ra is increased in
obesity and is correlated with BMI and IR (5,60-62). Mature adipocytes are capable of
producing inflammatory cytokines, but SVF cells and macrophages are the main source of
TNF, IL-6 and IL1 in obese wAT (30,38,45). TNF has been shown to inhibit adipocyte
differentiation by down-regulating the expression of transcription factors involved in
adipogenesis, stimulates lipolysis and contributes adipocyte apoptosis (63-65).
Increased infiltration of macrophages into the wAT is observed in obesity, and many
factors may be involved. Macrophage accumulation is associated with adipocyte
hypertrophy and increased expression of inflammatory factors in wAT, suggesting a role
of macrophages in wAT remodeling (38,40,66). The production of TNF is increased in
enlarged adipocytes, which triggers MCP-1 secretion from preadipocytes and endothelial
cells and subsequently attracts macrophages into the wAT (Figure 1) (65,67,68). TNF also
contributes to inflammatory status in AT by increasing the production of inflammatory
factors (40,56). Furthermore, hypoxia stimulates macrophage infiltration through hypoxia-
inducible factor (HIF)1 activation (69). Weight reduction decreases macrophage
infiltration into wAT (45).
In addition to adipocytes, PAI-1 is produced by other cell types of the SVF. PAI-1 is an
inhibitor of fibrinolysis and thus enhances the formation of thrombosis, leading to
increased cardiovascular disease risk (26). Furthermore, it has a role in adipocyte
differentiation, insulin signaling (70), tumor growth, metastasis and angiogenesis via
interaction with components of the ECM (26,68). Some studies have shown that the
expression of resistin is increased in obesity and is associated with the development of IR.
However, the results have demonstrated some discrepancy, and the role of resistin needs
to be further clarified (13,58,71).
2.3 INSULIN ACTION AND INSULIN RESISTANCE
In wAT, insulin regulates adipocyte biology by inducing the differentiation of
preadipocytes to mature adipocytes, stimulating glucose uptake and triglyceride synthesis
(lipogenesis),  and  inhibiting  the  release  of  fatty  acids  via  reduced  lipolysis  by  inhibiting
hormone-sensitive lipase (HSL) activity in mature adipocytes (72). In the liver, insulin
reduces the release of glucose by inhibiting glycogenolysis and increasing glucose storage
(10).  In  addition  to  traditional  insulin  target  tissues  (liver,  muscle,  AT),  insulin  activates
intracellular signaling pathways in many other tissues, like the vascular endothelium,
nervous system, kidney and brain (73,74).
In  wAT  and  skeletal  muscle,  insulin  action  is  initiated  by  binding  of  insulin  to  its
receptor and phosphorylation of insulin receptor substrates (IRSs), leading to activation of
phosphatidylinositol 3-kinase (PI3K) and downstream signaling molecules, including
protein kinase B (Akt/PKB) and atypical PKCs, with glucose transporter 4 (GLUT4)
translocation to the plasma membrane and glucose uptake, as illustrated in figure 2
(10,72,75). Insulin signaling can be effected by e.g. inflammatory factors and free fatty
acids  leading  to  IR  through  several  mechanisms  and  pathways  as  discussed  in  the
following section.
6Figure 2. Insulin action and factors involved in impaired insulin signaling and development of
IR in skeletal muscle and wAT.
Obesity-related IR has shown to precede type 2 diabetes (66). Complex mechanisms, as
shown in figure 2, include long-term energy surplus, increased fatty acid release and low-
grade inflammation (10). The term IR is defined as a decreased tissue response of
circulating insulin to stimulate glucose utilization in skeletal muscle, liver and wAT
(10,34,74). The metabolic effects of impaired insulin sensitivity in these tissues are
decreased insulin-stimulated glucose uptake and metabolism in adipocytes and skeletal
muscle, and decreased insulin-stimulated inhibition of both glucose production in liver
and lipolysis in wAT, leading to whole body IR (10,34,74).  However, the mechanisms are
not completely understood (66).
Several factors are capable of inducing IR (Figure 2). One of the primary causes, and
consequences, of IR is increased release of free fatty acids (FFA) from wAT due to
increased lipolysis. This induces ectopic lipid accumulation in liver, muscle, pancreas and
epicardium and blood vessel walls (34,38,51,54). FFA-induced IR may be mediated
through reduced phosphorylation of IRS-1 and GLUT4 translocation, activation of NF-B
pathway and inflammatory cytokine production (31,68). Lipodystrophy, the lack of wAT,
induces IR via increased circulating triglycerides and fatty acids in humans. Therefore, the
presence of functional wAT is needed for normal storing of lipids, adipokine secretion,
insulin sensitivity and glucose metabolism (2,76).
WAT is involved in maintaining glucose homeostasis and insulin sensitivity by taking
up glucose  through GLUT4 transporter  in  adipocytes  in  response to  insulin  (51).  Down-
regulation of GLUT4 expression and decreased GLUT4 translocation to plasma membrane
has been shown to contribute to the development of IR in adipocytes. However, in skeletal
muscle the expression of GLUT4 is not changed, and the impaired glucose uptake is due to
decreased translocation of GLUT4 to the plasma membrane (72,77).
Based on experimental and human studies, it could be proposed that also activation of
many inflammatory pathways are involved, which was first shown by Hotamisligil et al in
71993 (30,42,66). As mentioned earlier, several inflammatory factors, like TNF, IL1 and
IL-6 are increased in obesity and are also associated with the development of IR (66)
mainly through activation of inhibitor of nuclear factor kappa-B kinase subunit beta
(IKK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B) -
pathway, but also through other pathways, like c-Jun N-terminal kinase (JNK)1/2-pathway
(4,13,56,78).  TNF induces  IR  in  wAT  and  skeletal  muscle  by  phosphorylation  of  the
insulin receptor, IRS-1 and down-regulation of adiponectin and GLUT4 gene expression
and translocation (5,34,54,56,71). IL-6 induces IR through tyrosine phosphatase activation
or  interaction  between  suppressor  of  cytokine  signaling  (SOCS)  proteins  and  the  insulin
receptor (56). There is evidence showing that IL1 could stimulate IR in a similar way as
TNF (45,60). Furthermore, adipocyte hypertrophy leads to macrophage infiltration into
wAT, where they release inflammatory cytokines which can induce IR in neighboring
adipocytes via paracrine effects (10).
Weight reduction, caloric restriction and the use of neutralizing antibodies against
inflammatory factors have been shown to reduce inflammation and IR and increase anti-
inflammatrory factors in wAT (18,45,54,61,62,66).
2.4 CONSTITUENTS OF ADIPOSE TISSUE
There are two types of AT: white and brown (44,79). In addition to energy storage, wAT is
highly active metabolic and endocrine organ involved in modulating appetite, insulin
sensitivity, bone metabolism, inflammation and immunity (5,44). WAT is a heterogeneous
tissue composed of lipid-filled mature adipocytes and a stromal-vascular fraction (SVF)
that in turn is comprised of preadipocytes, fibroblasts, endothelial cells, immune cells and
several other cell types (13,30,51,74).
In human adults, most AT is white. There is also evidence that adults have functional
brown AT, which is involved in facultative nonshivering thermogenesis through the
action of UCP-1 (80-82). Brown adipocytes have multilocular lipid droplets and are
associated with fatty acid oxidation (83). It has been demonstrated that brown adipocytes
are  present  in  white  AT,  though  it  is  unclear  whether  they  originate  from  trans-
differentiating white adipocytes or de novo differentiating preadipocytes (84,85).
2.4.1 White adipose tissue remodeling
Preadipocytes can differentiate into lipid-filled mature adipocytes in a phenomenon
termed as adipogenesis (79). Adipogenesis is an ongoing process throughout the life-span
enabling enlargement of wAT during development of obesity (79). Recently, Spalding et al
proposed that the number of adipose cells is constant in adulthood in obese and lean
subjects indicating that there is a continuous turnover of adipose cells (86). In fact, 10% of
adipose cells are renewed annually in adulthood (86). Adipogenesis is highly regulated
system  by  transcription  factors  and  other  regulators  (21).  As  shown  in  figure  3,  the
preadipocyte differentiation into mature adipocyte is induced with a well characterized
differentiation cocktail and is associated with sequential activation of transcription factors,
notably CCAAT/enhancer binding proteins (C/EBP)-, peroxisome proliferator-activated
receptor  (PPAR)-, and C/EBP- and adipocyte-specific genes (40,41,87).
8Figure 3. Preadipocyte differentiation and factors involved in the process
During wAT enlargement and adipogenesis the change from a fibroblast-like
preadipocyte into mature adipocytes is associated with remodeling of the ECM (Figure 3)
(14,41) which takes place simultaneously with activation and repression of the
transcription factors (15). However, the molecular mechanisms have not been fully
defined (16). In addition, angiogenesis is strongly associated with adipogenesis and
angiogenesis enhances during wAT enlargement and development of obesity in mice (4).
2.4.2 Extracellular matrix in white adipose tissue
ECM is enclosing mature adipocytes and maintains the integrity and structure of wAT
(13,14,51) and is composed of collagens, adhesive glycoproteins and proteoglycans (15).
ECM regulates physiological and pathological processes in wAT, such as development
and tissue repair and inflammation (15). Signals from ECM to intracellular compartments
are  mediated  through  plasma  membrane  integrins  which  in  turn  are  involved  in  cell
proliferation, differentiation, migration, apoptosis, gene induction and fatty acid oxidation
in mitochondria (9,52). Components of the ECM are capable of modifying immune
functions, e.g. immune cell migration into and within inflamed tissues (88). The expression
of  ECM proteins  is  increased in  obesity  (11),  and many cell  types  of  wAT are  capable  of
producing ECM proteins (52). However, there is strong evidence that the ECM molecules
are predominantly expressed in SVF of wAT (52).
WAT  fibrosis,  defined  as  an  excessive  synthesis  of  various  ECM  molecules,  including
collagens (collagens I and III) and glycoproteins (laminin, fibronectin) (52,89), may link
obesity to diabetes or cardiovascular diseases in association with inflammation (16).
Recent  studies  have  demonstrated  that  collagen  VI  is  highly  expressed  in  obesity,  limits
wAT expansion and is associated with obesity-related comorbidities. There is also
9evidence that a loss of collagen VI in wAT leads to improvements of metabolic profile
(14,90,91). There is strong evidence that preadipocytes may contribute to the development
of fibrosis (9). It has been shown that preadipocytes are able to increase the production of
many ECM molecules in an inflammatory environment, and this is associated with
increased proliferation and migration of preadipocytes (15). It cannot be ruled out,
however, that also mature adipocytes could produce ECM proteins (52).
2.4.3 Extracellular matrix remodeling and factors involved
The amount of ECM molecules during development of obesity or after weight reduction is
balanced by the rate of their synthesis and degradation (14). This is regulated by several
factors (Table 2), like matrix metalloproteinases (MMPs) and their tissue inhibitors (14). In
addition, growth factors like transforming growth factor beta (TGF), and cytokines
(TNF, IL1, IL-6) modulate ECM synthesis (88,92). TGF, which is up-regulated in
human and animal models of obesity (9), is a major regulator of ECM synthesis through
induction of gene expression of matrix and tissue inhibitors of metalloproteinases (TIMPs)
(92). Moreover, TGF is suggested to be involved in enlargement of wAT and inhibition of
adipogenesis (93). Recently, apart from its role in adipogenesis, PPAR has been shown to
be an antifibrotic factor and to down-regulate the synthesis of type I collagen, possibly
through reduced TGF activity (14,94).
Table 2. Factors involved in ECM remodeling
Factors Effects on ECM
MMPs degradation of ECM components
TIMPs inhibition of ECM degradation
TGF synthesis of ECM components
cytokines modification of ECM through MMPs/TIMPs
PPAR down-regulation of ECM components
insulin modification of ECM through MMPs/TIMPs
adiponectin modification of ECM through MMPs/TIMPs
leptin modification of ECM through MMPs/TIMPs
angiotensin modification of ECM through MMPs/TIMPs
estrogen modification of ECM through MMPs/TIMPs
There are also other factors that are capable of modifying ECM synthesis. Insulin
regulates the production of ECM components through transcription of genes for protein-
modifying and –processing enzymes (95). Furthermore, adiponectin, leptin, angiotensin
and  estrogen  are  involved  in  the  modification  of  ECM  protein  expression  through
regulation of MMP/TIMP activity (96-98). These hormones and their receptors are
expressed in wAT. Thus, it could be postulated that they are capable of regulating ECM
remodeling also in wAT (98).
Little is known about the effect of nutrition or single nutrients, except obesity and
weight changes, on ECM remodeling in wAT. Although cellular interactions in wAT has
been studied extensively (14), the molecular mechanisms involved in ECM remodeling are
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poorly understood in humans (9), despite the fact that ECM is an important constituent of
wAT physiology (14).
2.5 EFFECT OF WEIGHT REDUCTION ON WHITE ADIPOSE TISSUE
BIOLOGY/FUNCTION
Lifestyle modification, such as weight reduction, healthy diet and increased physical
activity, has been shown to prevent many obesity associated co-morbidities and to reduce
the  risk  of  type  2  diabetes  in  long-term  and  to  improve  insulin  and  glucose  metabolism
(17,19). Even a modest weight reduction improves metabolic status and decreases the risk
factors associated with obesity (30), suggesting an essential role of wAT in obesity-related
complications (99). Weight loss is associated with a reduced production and expression of
inflammatory factors, and increased adiponectin secretion from wAT (18,30,45). Moreover,
weight loss is known to decrease macrophage infiltration and the expression of
inflammation-related genes in wAT (18,45,100).
A series of studies have aimed to identify new putative genes related to obesity and
type 2 diabetes. A genome-wide transcriptomics analysis performed on subcutaneous (sc)
wAT samples from persons with metabolic syndrome participating in the Gene Expression
in Obesity and Insulin Resistance (GENOBIN) study (20) demonstrated changes in the
expression of 105 genes in response to weight reduction, and at the same time glucose
metabolism and insulin sensitivity improved. The major gene clusters that responded to
weight reduction included ECM and cell death (20). Among the down-regulated genes
after weight loss were ECM-related gene microfibrillar-associated glycoprotein 5 (MFAP5)
and a calcineurin-like phosphoesterase domain containing 1 (CPPED1). These genes are
therefore interesting putative genes involved in obesity-related conditions (20).
2.5.1 Microfibrillar-associated protein 5 (MFAP5)
MFAP5, also known as MAGP-2 (microfibrillar-associated glycoprotein 2), is located in the
microfibrils  of  elastin  networks  in  a  number  of  tissues,  and  it  has  been  suggested  to  be
involved in cell signaling during microfibril assembly, elastinogenesis (101-103) and cell
survival (104,105) through activation of v3 integrin and focal adhesion kinase (FAK)
(105,106). MFAP5 has pro-angiogenic activity and it interacts with NOTCH1 either directly
or through NOTCH1 ligands (107,108). It seems that MFAP5 mediates cell specific
functions, because it has been shown to activate (108) or inhibit (107) NOTCH1 signaling
depending on the cell type involved. ECM is functionally important to wAT biology (14)
and  is  involved  in  wAT  inflammation.  As  a  constituent  of  ECM,  MFAP5  is  a  putative
molecule involved in wAT biology; in this regard it has not been studied before.
2.5.2 Calcineurin-like phosphoesterase domain containing 1 (CPPED1)
CPPED1 has been shown to be expressed in melanoma and peripheral blood mononuclear
cells (PBMCs) (109,110). However, the function of CPPED1 in wAT, in which we observed
down-regulation in gene expression after weight loss (20), is completely unknown. By
using EFICAz (Enzyme Function Inference by a Combined Approach), CPPED1 has been
predicted as an endopolyphosphatase, which degrades long polyphosphate chains into
shorter chains (111). Since macrophages infiltrate into wAT in obesity and cause
inflammatory responses, we hypothesized that CPPED1 could be a novel molecule
involved in wAT inflammatory processes.
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3 Aims of the Study
The increased low-grade inflammation in obesity with abnormal production of adipokines
and adipocytokines alters gene expression in wAT. Consequently, altered levels of
inflammatory factors and gene expression profile in wAT modulate insulin sensitivity by
targeting molecules regulating the insulin signaling pathway, eventually leading to IR, a
process  that  could  be  reversed  by  weight  reduction.  The  expression  of MFAP5 and
CPPED1 was down-regulated in response to weight reduction, supporting them as
putative genes involved in wAT biology. The general objective of this thesis work was to
study the roles of MFAP5 and CPPED1 in wAT biology, and particularly whether changes
in their gene expression in response to weight reduction are associated with the
magnitude of weight reduction.
Specifically,  the  aim  was  to  elucidate  the  possible  roles  of MFAP5 and CPPED1 in
controling adipocyte function, inflammation and glucose metabolism at the cellular level
using human peripheral tissues and adipocyte cell culture models. The aims in detail
were:
1. To identify the relationship between the expression of target genes and changes in
adiposity, glucose metabolism and inflammation
2. To elucidate the functions of target genes by RNA interference technology on
adipocyte metabolism and insulin sensitivity
3. To investigate the effect of inflammatory cytokines on the expression of target genes
13
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4 Materials and Methods
4.1 HUMAN STUDIES
4.1.1 Study populations and study designs
The  Gene  Expression  in  Obesity  and  Insulin  Resistance  (GENOBIN) Study—Originally, 75
overweight/obese (BMI 28-40 kg/m2) subjects aged 40 to 70 years were recruited to the
GENOBIN study as described earlier (20,112). The subjects had impaired fasting glucose
(fasting plasma glucose concentration 5.6 – 6.9 mmol/L) or impaired glucose tolerance (2-h
plasma glucose concentration 7.8 – 11.0 mmol/L) and at least two other features of the
metabolic syndrome according to the Adult Treatment Panel III criteria (113) as modified
by the American Heart Association (22). Subjects were randomly assigned to one of the
following groups: a weight reduction group (WR, n=28), an aerobic exercise training group
(n=15), a resistance exercise training group (n=14) or a control group (n=18) (20,112).
Subjects were matched for age, gender, BMI and the status of glucose metabolism. In the
current thesis work, only the data from the weight reduction and control groups were
included and analyzed (study I and unpublished, complementary data).
The weight reduction group had an intensive weight reduction period lasting for 12
weeks  during  which  study  subjects  followed  detailed  instructions  given  by  a  clinical
nutritionist. These instructions were based on a 4-day dietary record and an interview.
Between weeks 12 and 33 the aim was to maintain the achieved reduction in weight. The
control group was asked not to change their lifestyle habits.
The Kuopio obesity surgery (KOBS) study—The design of the study has been reported
earlier (114). All  subjects  undergoing  the  Roux-en-Y  gastric  bypass  surgery  at  Kuopio
University Hospital were recruited to this study. Altogether 95 morbidly obese (BMI 45.0 ±
5.9 kg/m2) subjects aged 36 to 54 years participated in the study. Open subcutaneous wAT
biopsies and blood samples were drawn at baseline and after 12 months of follow-up to
collect wAT and PBMC samples, respectively. Weight loss in this study during the follow-
up period was -24±9%. Gene expression data from the subcutaneous wAT and PBMC
samples at baseline and at follow-up were analyzed in this study.
4.1.2 Approval of the Ethics Committee
The clinical studies (study I and unpublished, complementary data) and experiments
concerning SVF isolation and immunohistochemistry (study II and unpublished,
complementary data) were performed in accordance with the standards of the Helsinki
Declaration and the Ethics Committee of the District Hospital Region of Northern Savo
approved the study plan. All participants gave a written informed consent.
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4.1.3 Methods
4.1.3.1 Anthropometric and biochemical measurements (study I and unpublished,
complementary data)
Anthropometric and biochemical measurements were taken at baseline and end of the
intervention. Weight and height were measured in light indoor clothes, and BMI was
calculated as weight (kg) divided by height (m) squared. Waist circumference was
measured halfway between the lowest rib and iliac crest.
In  the  GENOBIN  study,  plasma  glucose  concentration  was  measured  with  the
hexokinase method (Thermo Clinical Labsystems, Vantaa, Finland) and serum insulin was
determined with a chemiluminescence sandwich method (ACS 180 Plus Automated
Chemiluminescence System; Bayer Diagnostics, Tarrytown, NY). Hs-CRP was measured
by Immage Immunochemistry System (Immulite 2000; DPC, 134 Los Angeles, CA). TNF,
IL1 and  IL1Ra  concentrations  were  measured  by  solid  phase  ELISA  (Quantikine,  R&D
Systems, Minneapolis, MN). Commercial RIA kit (Linco Research Inc., St. Louis, MO) was
used for the analysis of serum leptin concentration and ELISA kit (R&D Systems Inc., MN)
for serum adiponectin measurement. Glucose metabolism was measured using an oral 2-
hour glucose tolerance test (OGTT) and frequently sampled intravenous glucose tolerance
test (FSIGT) according to the Minimal Model method (115) at baseline and at the end of
the intervention (20).  Insulin sensitivity index (SI), glucose effectiveness (SG) and acute
phase insulin response to glucose (AIR) were calculated by the MINMOD Millenium
software (116).
In the KOBS study, plasma glucose was analyzed with an enzymatic hexokinase
photometric assay (Konelab Systems Reagents, Thermo Fischer Scientific, Vantaa, Finland)
and serum insulin concentrations with an immunoassay (ADVIA Centaur Insulin IRI, no
02230141, Siemens Medical Solutions Diagnostics, Tarrytown, NY).
4.1.3.2 Adipose tissue biopsies (studies I and III)
WAT samples of the GENOBIN study were taken by a needle biopsy after a 12-hour
overnight fasting from superficial abdominal subcutaneous wAT at the midpoint between
umbilicus and iliac crest at baseline and after the intervention under local anesthesia
(lidocaine  10  mg/ml  without  adrenaline)  to  collect  0.5  -  5  g  of  wAT.  WAT samples  were
washed twice with phosphate-buffered saline (PBS) and treated with RNAlater according
to  the  instructions  provided  by  the  manufacturer  (Ambion,  Austin,  TX,  USA).  After
removal of RNAlater the samples were stored in -80°C until used for RNA extraction (20).
WAT samples of the KOBS study were taken as an open biopsy from subcutaneous and
visceral wAT during the Roux-en-Y gastric bypass surgery operation (at baseline) and 12
months after the surgery (follow-up) under local anesthesia (lidocaine 10 mg/ml with
adrenaline) (114).
4.1.3.3 Isolation of PBMC cells (unpublished, complementary data)
PBMCs of the GENOBIN study were isolated from anticoagulated peripheral blood by
density centrifugation for 10 min at 900 g and for another 10 min at 300 g using a reagent
(Lymphoprep;  Axis-Shield,  Oslo,  Norway)  (100),  and  PBMCs  of  the  KOBS  study  were
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collected from whole blood samples with BD vacutainer CPTTM Tubes according to the
manufactures protocol (Becton Dickinson, USA) (114).
4.1.3.4 Isolation of stromal-vascular fraction cells and mature adipocytes (study II and
unpublished, complementary data)
Subcutaneous abdominal wAT samples were taken by needle biopsy from eight male
donors (age 59.2 ± 7.7 years, BMI 25.7 ± 3.26 kg/m2, fasting plasma glucose and insulin (5.8
± 0.68 mmol/L, 10.0 ± 6.15 mU/L), respectively) under local anesthesia (lidocaine 10
mg/mL). AT samples were washed twice with phosphate-buffered saline (PBS) and
digested with type II collagenase. The cell suspension was centrifuged (400 g, 4 min,
+25C) to obtain SVF cells (cell pellet) and mature adipocytes.
4.2 CELL STUDIES
4.2.1 Methods
4.2.1.1 Differentiation of SGBS cells (studies II and III)
Human  preadipocyte  cell  strain  Simpson  -  Golabi  -  Behmel  syndrome  (SGBS)  is
characterized by a high capacity for adipogenic differentiation, and are derived from
human SVF of subcutaneous wAT (117). The preadipocytes were cultured at 37C in a
humidified atmosphere of 5 % CO2 in air. The cells were maintained in basal medium 1,
OF [DMEM/F12 Nut mix (Lonza, Verviers, Belgium) medium, 33 μmol/L biotin (Sigma-
Aldrich), 17 μmol/L pantothenate (Sigma-Aldrich), 1% antibiotics (penicillin/streptomycin,
Lonza)], supplemented with 10% FBS (Lonza) until reaching confluence.
To induce adipocyte differentiation, cells were washed several times with PBS (Lonza)
and cultured in basal medium 2, 3FC [DMEM/F12, 33 μmol/L biotin, 17 μmol/L
pantothenate, 1% antibiotics, 10 μg/mL transferrin (Sigma-Aldrich), 20 nmol/L insulin
(Sigma-Aldrich), 0.1 μmol/L hydrocortisone (Sigma-Aldrich), 0.2 nmol/L
triiodothyronine], supplemented with 25 nmol/L dexamethasone (Sigma-Aldrich), 0.5
μmol/L 1-methyl-3-isobutylxanthine (IBMX, Sigma-Aldrich) and 2 μmol/L BRL 49653
(rosiglitazone,  PPAR agonist,  Cayman  Chemical,  USA)  for  4  days.  After  4  days,  the
medium was replaced with 3FC medium supplemented with 25 nmol/L dexamethasone
and 0.5 μmol/L IBMX for 3 days. After 3 days, the medium was replenished twice a week
with 3FC medium.
4.2.1.2 Oil Red O –staining (study II)
SGBS preadipocytes were grown and differentiated as described above. At indicated time
points  (shown  in  Figure  7F)  the  cells  were  washed  with  PBS  and  fixed  in  4%
paraformaldehyde (PFA) for 5 min and after discarding, fresh PFA was added for 1.5h at
room temperature (RT). After fixation, the cells were washed twice with milliQH2O and
once with 60% isopropanol for 5 min at RT. Next, Oil Red O solution (filtered 0.3 g/100 mL
isopropanol in milliQH2O 3:2 (v/v)) was added and incubated for 25min at RT. Finally, the
cells  were  washed  three  times  with  milliQH2O, and the cells were visualized using
microscopy (Nikon Eclipse TE300, Japan).
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4.2.1.3 Cytokine treatments (study II and unpublished, complementary data)
SGBS preadipocytes were cultured in 12-well plates until they reached confluence and
were  washed  once  with  PBS.  The  medium  was  changed  to  pre-incubation  medium  1
[DMEM/F12 Nut mix (1:1) supplemented with 17 μmol/L pantothenate and 33 μmol/L
biotin] for 24h. The following day the cells were cultured in the presence of TNF- (Sigma-
Aldrich), IL1 (PeproTech Inc., NJ, USA), TGF1 (ProSpec-Tany TechnoGene Ltd.,
Rehovot, Israel) or IL-6 (PeproTech) with various concentrations (0.1–10.0 ng/mL) and
several time points (0, 3, 6, 12, 24, 48, 72h). Control cells were treated with appropriate
vehicle and wells incubated in pre-incubation medium 1 without cytokines were used as
controls.
For cytokine-treated mature adipocytes, preadipocytes were cultured in 12-well plates
and induced into mature adipocytes as described in 4.2.1.1. On day 14 of differentiation
the medium was changed to pre-incubation medium 2 (DMEM/F12 Nut mix (1:1)
supplemented with 10 μg/mL transferrin, 33 μmol/L biotin and 17 μmol/L pantothenate)
for 24h. The cytokine treatment was performed for fully differentiated cells on day 15 of
post-differentiation. The cells were cultured in the presence of cytokines as mentioned
above. Control cells were treated with appropriate vehicle and wells incubated in pre-
incubation medium 2 without cytokines were used as controls.
In study II, the data from the cytokine treatment of TNF-, IL1, TGF1 and IL-6 for 48h
in  preadipocytes  is  included,  showing  the  most  pronounced  effects  on  the  mRNA
expression of MFAP5. In addition, the data from the cytokine treatment of TNF- for 24h
both  in  preadipocytes  and  adipocytes  is  included  in  this  thesis  work,  showing  the  most
pronounced effects on the mRNA expression of CPPED1.
4.2.1.4 Knock-down experiments (studies II and III)
RNA interference (RNAi) was used for knocking down the expression of the target gene in
mature adipocytes. ON-TARGETplus SMARTpool SiRNA was used and purchased from
Dharmacon  (Thermo  Scientific  Dharmacon®,  Lafayette,  USA).  The  four  target  siRNA
sequences included in the pool of the target genes are shown in table 3. The negative
control  for  the  siRNA (scrambled)  used in  the  experiments  was Allstars  negative  control
SiRNA  (Qiagen,  Valencia,  CA,  USA).  The  siRNA  was  transfected  into  the  cell  by  using
HiPerFect transfection reagent (Qiagen) according to the instructions.
The SGBS cells were cultured in 12-well plates and induced into mature adipocytes as
described in 4.2.1.1. On day 14 of differentiation, the medium was replaced to DMEM/F12
Nut mix (1:1) supplemented with 33 μmol/L biotin, 17 μmol/L pantothenate, 10 μg/mL
transferrin, and 20 nmol/L insulin. The cells were transfected with 20 nmol/L of MFAP5
and 50 nmol/L of CPPED1 siRNA and incubated for indicated time points. Knock-down of
target gene expression was confirmed by quantitative reverse-transcriptase polymerase
chain reaction (RT-qPCR) and western blot.
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Table 3. The siRNA sequences of the target genes used in this thesis work
Gene siRNA sequence
MFAP5 GGUCAAUAGUCAACGAGGA
CGAUGUGACUCAAGCGACU
GCCUAAUAGUUAAUACGAA
GCAGUUGUCUAGUCGGGAA
CPPED1 AGAAAAUUGUUCACCGAUA
UAAAUGCACUAAUGCGAAA
CGGAGGACCUGAAGCGAGU
CCUUUAAAAUGGAGCGAAU
4.2.1.5 Insulin-stimulated glucose uptake (studies II and III)
The  SGBS  preadipocytes  were  cultured  in  12-well  plates  and  induced  into  mature
adipocytes as described in 4.2.1.1. On day 17 of differentiation, the cells were washed
twice with PBS and pre-incubated with Krebs Ringer HEPES (KRH)-buffer [20 mmol/L
HEPES (pH 7.4), 118 mmol/L NaCl, 4.8 mmol/L KCl, 2.5 mmol/L CaCl2, 1.2 mmol/L
MgSO4,]. After pre-incubation, the cells were incubated in the presence of 100 nM
Wortmannin, a PI3K-specific inhibitor (when indicated, study III), and followed by
incubation with 1 μmol/L insulin. Next, 0.5 μCi/mL of labeled 2-Deoxy-D-[3H] glucose
(Amersham TRK672, GE Healthcare, UK) and 0.2 mmol/L of D-glucose were added. The
reaction was terminated by placing the cells onto the ice and washing 3 times with ice-cold
PBS.
The cells were solubilized with 0.2 N NaOH/well, and the cell lysate was transferred to
a 2.0 mL eppendorf tube, and scintillation liquid was added for radioactivity counting.
Glucose uptake was normalized to protein content as measured from the remaining cell
lysate  by  using  the  Bio-Rad  protein  assay  (Bio-Rad  DC Protein Assay, Bio-Rad
Laboratories, Hercules, CA, USA). Protein concentrations were measured according to
manufactures instructions (DC Protein Assay, BIORAD) by using Wallac 1420.
4.2.1.6 Immunohistochemistry (study II and unpublished, complementary data)
Immunohistochemistry was performed to test for localization of the target protein
expression in human abdominal subcutaneous wAT samples obtained from subjects (age
54 ± 17.4 years, BMI 35 ± 9.3 kg/m2) undergoing an elective surgery at the Kuopio
University Hospital using NovoLinkTM Min Polymer Detection system (Novocastra
laboratories Ltd, UK). Paraffin-embedded human wAT sections were de-paraffinized in
xylene and rehydrated in decreasing concentrations of ethanol, via sequential steps with
interposed washing steps. Endogenous peroxidase activity was neutralized using
Peroxidase Block and this was followed by incubation with Protein Block. WAT sections
were stained with 1:10 or 1:500 diluted polyclonal antibody against MFAP5 (Sigma-
Aldrich,  St.  Louis,  MO,  USA)  or  1:10  diluted  polyclonal  antibody  against  CPPED1  in  a
humidity chamber for 1h at room temperature. The wAT sections were incubated with
Post Primary block and further with a polymer that recognized mouse and rabbit
immunoglobulins. Peroxidase activity was developed with substrate/chromogen, 3,3' -
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diaminobenzidine. The sections were counterstained with Hematoxylin and coverslipped.
A negative control slide without a primary antibody was included for assessing non-
specific staining. Results were interpreted using a light microscope (Zeiss AxioImager M2
(Zeiss, Oberkochen, Germany)) and a camera (Zeiss AxioCam MRc).
4.2.1.7 Immunofluorescence (unpublished, complementary data)
Preadipocytes  were  grown  on  Permanox  slides  (Thermo  Scientific)  at  80%  confluency
which after the cells were induced to differentiation as mentioned in 4.2.1.1. Preadipocytes
and differentiated adipocytes (day 11 post-differentiation) were washed twice in PBS and
fixed with 4% paraformaldehyde (PFA). Next, the cells were washed twice in PBS and
plasma membranes were permeabilized in PBS containing 0.01% Saponin (Sigma-Aldrich).
The cells were incubated with Image-iT FX Signal enhancer to reduce background and
washed twice with PBS. After blocking (0.2 mol/L Glycine + 5% FBS in PBS) the cells were
incubated with 1:10 dilution of a rabbit anti-CPPED1 antibody (Sigma-Aldrich) at 4C
overnight. The next day, after three washes with PBS, the cells were incubated with 1:1500
dilution of an Alexa Fluor 568 goat anti-rabbit secondary antibody (Molecular Probes) and
1:2000 dilution of a Hoechst 33258 nuclear stain (Molecular Probes). After washing with
wash buffer and PBS, the cells were mounted with PermaFluor™ Aqueous Mounting
Medium (Thermo Scientific) and visualized using an Olympus confocal microscope
(OLYMPUS DP50, Japan).
4.2.1.8 Western blot (studies II and III)
In study II, adipocytes for total protein extraction were rinsed twice with PBS and then
lysed in T-PER buffer (PIERCE, Rockford, USA) freshly supplemented with 1 mM Na3VO4,
1  mM NaF,  and proteinase  inhibitor  cocktail  (Roche Diagnostics,  Germany),  followed by
centrifugation (13000 rpm, 15 min, +4C) and removal of the soluble fraction. The
remaining cell pellet was lysed in UREA buffer [PBS (pH 7.4), 5.0 M Urea (Sigma-Aldrich),
2.0 M Thiourea (Sigma Aldrich), 50 mM DTT (Sigma-Aldrich), 0.1% SDS], followed by
centrifugation (13000 rpm, 15 min, +4C) and removal of supernatant which consists of
insoluble fraction (membranes etc.). The protein concentration was determined using
Pierce 660nm Protein Assay (Pierce).
In study III,  adipocytes  were  rinsed twice  with  PBS and then lysed in  RIPA Lysis  and
Extraction Buffer (PIERCE, Rockford, USA) freshly supplemented with 1 mM EDTA, 1
mM PMSF, 1 mM Na3VO4, 1 mM NaF, and proteinase inhibitor cocktail (Roche
Diagnostics, Germany), followed by centrifugation (13000 rpm, 15 min, +4C) and removal
of soluble fraction. The protein concentration was determined using the Bio-Rad protein
assay (Bio-Rad DC Protein Assay, BioRad).
Equal amounts of protein (10 – 20 μg) was separated using sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), transferred to the polyvinylidene
fluoride (PVDF) membrane (GE Healthcare, Buckinghamshire, UK). A Rabbit anti-human
MFAP5, ADAM12 and TGF1 (Abcam, Cambridge, UK) or a mouse anti-human IL-6 or a
Rabbit anti-human CPPED1 and ADIPOQ (Sigma-Aldrich) were used as primary
antibodies. The primary antibodies were detected with goat anti-rabbit or –mouse
peroxidase conjugated secondary antibody (Pierce). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, Abcam) was used for normalization. Signals were detected
using Amersham ECL Advance Western Blotting Detection Kit (GE Healthcare) and
ImageQuant Capture-RT ECL for Windows version 1.0.1 (GE Healthcare). In study II,
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densitometric analysis was performed by Scion Image for Windows version Alpha 4.0.3.2
(Scion Corporation, USA) and in study III by ImageJ version 1.45s (ImageJ, National
Institutes of Health, Maryland, USA).
4.2.1.9 High molecular weight (HMW) adiponectin enzyme-linked immunosorbent
assay (ELISA) (study III)
In study III, mature adipocytes were treated with 50 nM CPPED1 siRNA  for  48h  as
mentioned in 4.2.1.4, and the effect of knock-down on HMW adiponectin secretion into the
conditioned  medium  was  measured  with  ELISA  (Millipore,  St.  Charles,  Missouri,  USA)
with a sensitivity of 0.5 ng/mL. After treatment the conditioned medium was collected,
centrifuged at 1000 rpm for 10 min at room temperature (RT) and stored -80C until
measured. The samples were pre-treated with digestion solution that selectively degraded
LMW and MMW adiponectin isoforms by proteolytic actions to enable measurement of
HMW adiponectin levels. The standards, digestion controls and samples were added into
the microtiter plate and incubated at RT for 2h with shaking. Next, unbound materials
were washed with wash buffer and afterwards biotinylated polyclonal anti-adiponectin
antibody was added and incubated at RT for 1h with shaking. Again, unbound materials
were washed with wash buffer. Next, streptavidin-horseradish peroxidase conjugate was
added for 30 min at RT with shaking and afterwards washed of excess of free enzyme
conjugates with wash buffer. Next, TMB substrate was added for 5 to 20 min with shaking,
and the enzyme activity was measured spectrophotometrically at 450-590 nm. The increase
in absorbance is directly proportional to the amount of captured human HMW
adiponectin.
4.2.1.10 Quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR)
(studies I-III)
Total RNA from wAT samples of the GENOBIN study was extracted using the TRIzol
method (Invitrogen, Carlsbad, CA, USA) followed by further purification with RNeasy
Mini  Kit  columns (Qiagen,  Valencia,  CA,  USA).  For  the  wAT and PBMC samples  of  the
KOBS study,  PBMCs of  the  GENOBIN study,  SVF cells,  mature  adipocytes  and cultured
SGBS cells, the RNeasy Mini Kit was used for the total RNA extraction (Qiagen). The High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used for cDNA
synthesis of AT and PBMC samples and iScript cDNA synthesis kit (Bio-Rad) for SVF cells,
mature adipocytes and SGBS cells according to instructions provided by the manufacturer.
RT-qPCR with TaqMan® chemistry  (Applied Biosystems ®)  by using ABI  Prism 7500
analyzer (Applied Biosystems) was used for the determination of mRNA expression
levels, and the TaqMan gene expression assays that were used in this thesis work are
presented in table 4. The analysis for the relative quantity of a specific gene before and
after  the  intervention  in  wAT  and  PBMCs  of  the  GENOBIN  study  was  performed  as
follows. Quantities of gene expression on each plate were corrected by the calibrator of the
corresponding plate and the relative amount of expression was normalized with the
corresponding  values  of  endogenous  control  cyclophilin  A1  (PPIA)  expression  for  wAT
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)  for  PBMC  samples  of  the
GENOBIN  study.  Final  gene  expression  levels  are  expressed  as  arbitrary  units  (AU).
Expression of target genes were normalized to PPIA expression for wAT samples of the
KOBS study, SVF cells, mature adipocytes and SGBS cells, and GAPDH for PBMC samples
of the KOBS study. Expression of the target genes in wAT and PBMC samples of the KOBS
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study, SVF cells, mature adipocytes and in cultured SGBS cells were normalized to the
endogenous control using the formula 2^-ddCt (118).
Table 4. Genes investigated in this thesis work
Study Tissue/
cells
Gene
symbol
Gene
description
Assay ID Function
I,II AT,
SGBS
ADAM12 a disintegrin and
metalloproteinase
domain 12
Hs01106111_m1 involved in cell-cell, cell-
matrix interactions, and
early steps of adipogenesis
I AT ADAM22 a disintegrin and
metalloproteinase
domain 22
Hs00244640_m1 involved in cell-cell and cell-
matrix interactions
III AT,
SGBS
ADIPOR1 adiponectin
receptor 1
Hs00360422_m1 a receptor for adiponectin
through which adiponectin
regulates fatty acid
catabolism and glucose
uptake by adiponectin
III AT ADIPOR2 adiponectin
receptor 2
Hs00226105_m1 mediates increased AMPK,
PPAR ligand activity, fatty
acid oxidation and glucose
uptake by adiponectin
I-III AT,
SGBS
ADIPOQ adiponectin Hs00605917_m1 involved in insulin
sensitivity and glucose
uptake, fatty acid oxidation
and inflammation
I AT CCND2 cyclin D2 CCND2 – E4 involved in regulating G1/S
transition of cell cycle
III AT,
PBMC,
SGBS
CPPED1 calcineurin-like
phosphoesterase
domain 1
Hs00217887_m1 unknown function, predicted
to be endopolyphosphatase
III AT,
SGBS
CPT1B carnitine
palmitoyltransfera
se 1B
Hs00189258_m1 catalyzes long-chain fatty
acid beta-oxidation in
muscle mitochondria
III PBMC,
SGBS
GAPDH glyceraldehyde-3-
phosphate
dehydrogenase
Hs99999905_m1 reference gene, involved in
carbohydrate metabolism
II,III SGBS GLUT1 glucose
transporter 1
Hs00892681_m1 responsible for constitutive
or basal glucose uptake
II,III SGBS GLUT4 glucose
transporter 4
Hs00168966_m1 Insulin-regulated facilitative
glucose transporter
III AT,
PBMC
IKBKB
(IKK)
inhibitor of kappa
light polypeptide
gene enhancer in
B-cells, kinase
beta
Hs00233284_m1 plays an essential role in
the NF-B signaling
pathway
I-III AT,
SGBS
IL1 interleukin 1 beta Hs00174097_m1 involved in the
inflammatory response
I,III AT IL1Ra interleukin 1
receptor
antagonist
Hs00277299_m1 Inhibits the activity of
interleukin-1
I-III AT,
SGBS
IL-6 interleukin 6 Hs00174131_m1 functions in inflammation
and the maturation of B
cells
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I-III AT,
SGBS
LEP leptin Hs00174877_m1 a major role in the
regulation of body weight,
involved in the regulation of
immune and inflammatory
responses, hematopoiesis,
angiogenesis
I,II AT,
SGBS
MFAP5 microfibrillar-
associated protein
5
Hs00969606_m1 Component of the elastin-
associated microfibrils
III AT,
PBMC
NFKBIA
(IKB)
nuclear factor of
kappa light
polypeptide gene
enhancer in B-
cells inhibitor,
alpha
Hs00153283_m1 Inhibits the activity of
dimeric NF-B
III AT,
PBMC
NFKBIB
(IKB)
nuclear factor of
kappa light
polypeptide gene
enhancer in B-
cells inhibitor,
beta
Hs00182115_m1 Inhibits NF-B by
complexing with and
trapping it in the cytoplasm
I,II AT,
SGBS
NOTCH1 notch1 Hs01062012_m1 Affects the implementation
of differentiation,
proliferation and apoptotic
programs
I AT NOTCH2 notch2 Hs01050729_m1 Affects the implementation
of differentiation,
proliferation and apoptotic
programs
I-III AT,
SGBS
PPAR2 peroxisome
proliferator-
activated receptor
gamma 2
PPARgamma2_REVP a regulator of adipocyte
differentiation and glucose
homeostasis
I-III AT,
SGBS
PPIA peptidylprolyl
isomerase A
(cyclophilin A)
Hs99999904_m1 accelerate the folding of
proteins
I,II AT,
SGBS
TGF1 transforming
growth factor,
beta 1
Hs00932734_m1 regulator of ECM production
and is involved in
proliferation, differentiation,
and other functions in many
cell types
I,III AT TNF tumor necrosis
factor alpha
Hs00174128_m1 involved in cell proliferation,
differentiation, apoptosis,
lipid metabolism, and
impairs insulin signaling
4.3 STATISTICAL ANALYSES
4.3.1 Human studies
The GENOBIN study—The data were analyzed using the SPSS software for Windows
version 14.0 (SPSS Inc., Chicago, IL, USA). Data are given as mean  SD, unless otherwise
indicated. The normality of distributions of the variables was tested with the Kolmogorov-
Smirnov test with Lilliefors' significance correction. Logarithmic transformation was used
to achieve normal distribution whenever needed (indicated in the tables and figures).
General linear models (GLM) for univariate analysis were used to test the difference in
fold change values of mRNA expression between the groups. A paired samples t-test was
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used for comparing the baseline and endpoint measurements within the study group.
Correlation analyses were done using Pearson's correlation coefficient. Partial correlation
analysis with adjustment for weight at baseline and gender was used when appropriate.
The  WR  and  control  groups  were  combined  in  the  correlation  analysis  at  baseline  and
when studying the correlations of change- values because the participants represent a
similar population in the beginning of the study. Thus, the participants were homogenous
regarding the selection criteria. After the intervention the two treatment groups were
analyzed separately because of potential treatment effect. A value of p<0.05 was
considered statistically significant.
The KOBS study—The expression data were analyzed using the SPSS software for
Windows version 14.0 (SPSS Inc., Chicago, IL, USA). Data are given as mean  SD, unless
otherwise indicated. Paired samples t-test was used for comparing the baseline and
endpoint gene expressions.
4.3.2 Cell studies
Results of the SVF cells, mature adipocytes and SGBS cell culture studies were analyzed
using the GraphPad Prism5 software for Windows version 5.03 (GraphPad Software, San
Diego California USA), and the results are expressed as mean  SEM. Statistical
significance was determined with the independent samples t-test,  one-way  analysis  of
variance with Bonferroni’s correction for multiple comparisons, or one-sample t-test
(indicated in figures). A value of p<0.05 was considered statistically significant.
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5 Results
5.1 HUMAN STUDIES (study I and unpublished, complementary data)
Baseline values for body weight, BMI, fasting plasma glucose and serum insulin
concentration in the GENOBIN and KOBS studies are presented in table 5. Participants in
the KOBS study were younger, morbidly obese and their serum insulin levels were much
higher than in the GENOBIN study.
Table 5. Baseline characteristics of the GENOBIN and KOBS studies
GENOBIN
(n=46)
KOBS
(n=95)
Age, years 59 ± 7 45 ± 8
Body mass index, kg/m2 32.9 ± 3.2 45.0 ± 6.3
Fasting plasma glucose, mmol/L 6.2 ± 0.4 6.7 ± 1.7
Fasting serum insulin, mU/L 11.5 ± 5.4 22.4 ± 22.0
5.1.1 Gene expression of MFAP5 and CPPED1 in adipose tissue of the GENOBIN study
(studies I and III) and in adipose tissue and peripheral blood mononuclear cells of the
KOBS study (unpublished, complementary data)
Previously published reductions in MFAP5 and CPPED1 expression in wAT after weight
reduction using Affymetrix microarrays (20) were confirmed with RT-qPCR (Figure 4). As
shown in figure 4A, MFAP5 expression in wAT decreased by 13% (p=0.017) in response to
weight loss, while no change was observed in the control group (data not shown). MFAP5
was not expressed in PBMCs of the GENOBIN study (data not shown).
As shown in figure 4B, RT-qPCR results confirmed the previously published reduction
in the expression of CPPED1 in  wAT  after  weight  loss  in  the  GENOBIN  study  using
microarray (study III) (20). We demonstrated a similar decrease in PBMCs of the
GENOBIN and KOBS studies that was seen in wAT samples of the GENOBIN study after
weight loss (Figure 4C). The down-regulation of CPPED1 expression in  wAT along with
weight loss could not be verified in wAT samples from the KOBS study (Figure 4B).  The
expression of CPPED1 did not change in the control group in wAT or PBMC samples of
the GENOBIN study (data not shown).
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Figure 4. (A) A relative mRNA expression of MFAP5 at baseline and after weight loss (follow-
up) in AT of the GENOBIN study. (B) A relative mRNA expression of CPPED1 at baseline and
after weight loss (follow-up) in AT and (C) in PBMCs of the GENOBIN and KOBS studies. The
values are expressed as relative gene expression levels normalized to endogenous control PPIA
for  the  AT  samples  and GAPDH for  the  PBMC  samples.  p<0.05  was  considered  statistically
significant. The comparisons were made within groups: black bars; expression at baseline,
white bars; expression after the follow-up.
26
5.1.2 Correlation analyses
5.1.2.1 Correlation of MFAP5 with anthropometric and biochemical measures and with
selected genes (study I)
Correlation analyses at baseline in the GENOBIN study showed that the expression of
MFAP5 mRNA correlated positively with body mass index (Table 6). Moreover, the
change in MFAP5 mRNA expression correlated with the change of body fat mass (r=0.392,
p=0.009). The expression of MFAP5 correlated with fasting serum insulin concentration at
baseline even after adjustment for body weight (Table 6). There was no correlation
between MFAP5 mRNA expression and fasting plasma glucose levels.
Furthermore, the expression of MFAP5 correlated negatively with concentration of
fasting serum adiponectin and positively with serum concentration and wAT expression
of leptin (Table 6). The change of MFAP5 expression level correlated significantly with the
change of adiponectin expression in wAT (r=0.433, p=0.004). Moreover, a positive
correlation was also found between MFAP5 expression and fasting plasma IL1Ra
concentrations, and a negative correlation with fasting plasma IL1 concentrations
(adjusted for body weight). MFAP5 expression did not correlate with the gene expression
level of IL1Ra and IL1 in subcutaneous wAT (Table 6).
Interestingly, MFAP5 expression correlated positively with the mRNA expression of a
master regulator of adipogenesis, PPAR,  cyclin  D2  (CCND2) and disintegrin and
metalloproteinase domain 12 (ADAM12) at baseline when adjusted for body weight (Table
6). Furthermore, the change of MFAP5 expression  level  correlated  with  the  change  of
ADAM12 expression in wAT (r=0.343, p=0.026) when adjusted for the change of body
weight.
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Table 6. Baseline partial correlations of MFAP5 mRNA  expression  in  subcutaneous  wAT  with
anthropometric, biochemical measures, and with selected genes expressed in subcutaneous
wAT in the combined weight reduction and control groups.
Groups combined
(n=46)
0 wk
ra p
Anthropometric and
biochemical measures
Body mass index
(kg m-2)b 0.369#### 0.014
Body weight (kg)b 0.043### 0.785
Body fat mass (kg)b 0.277#### 0.069
Waist circumference (cm) 0.282### 0.071
SI ((mU l
-1)-1 x min-1) -0.260## 0.101
fS-adiponectin (μg/ml) -0.378### 0.014
fS-leptin (ng/ml) 0.361### 0.019
fS-insulin (pmol/l) 0.397## 0.010
fP-glucose (mmol/l) 0.132## 0.41
fS-TNF (pg/ml) -0.162### 0.305
fP-IL1 (pg/ml) -0.401### 0.009
fP-IL1Ra (pg/ml) 0.347### 0.024
hsCRP (mg/l) -0.021### 0.895
Gene expression in
adipose tissue (AU)
LEP 0.338### 0.028
ADIPOQ 0.033### 0.838
PPAR 0.511### 0.001
TNF 0.132### 0.404
IL1 0.071## 0.659
IL1Ra 0.106### 0.504
IL-6 0.007### 0.966
TGF1 0.25# 0.12
NOTCH1 -0.277# 0.083
NOTCH2 0.191# 0.239
CCND2 0.523### <0.001
ADAM22 0.248### 0.114
ADAM12 0.584### <0.001
Values were logarithmized for analyses when appropriate. a adjusted for body weight (kg); b correlation
analyses done using Pearson's method, no adjustments; # n = 41; ## n = 42; ### n = 43; #### n = 44; SI
=  insulin  sensitivity  index;  fS  =  fasting  serum;  fP  =  fasting  plasma;  TNF =  tumour  necrosis  factor
alpha; IL1 = interleukin 1 beta; IL1Ra = interleukin 1 receptor antagonist; hsCRP = high sensitivity C
reactive  protein;  AU  =  arbitrary  unit;  LEP  =  leptin;  ADIPOQ  =  adiponectin;  PPAR =  Peroxisome
proliferator-activated receptor gamma; IL-6 = interleukin 6; TGF1 = transforming growth factor beta 1;
NOTCH1 = notch1 preproprotein; NOTCH2 = notch2 preproprotein; CCND2 = cyclin D2; ADAM22 = A
disintegrin and metalloproteinase domain 22; ADAM12 = A disintegrin and metalloproteinase domain 12;
bolded font indicates a statistically significant correlation (p<0.05)
5.1.2.2 Correlation of CPPED1 with selected genes (unpublished, complementary data)
Due  to  down-regulated  expression  of CPPED1 in  PBMCs  of  both  human  studies  and  in
wAT in the GENOBIN study, we examined whether CPPED1 expression correlated with
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the expression of inflammatory genes in wAT and PBMCs from the GENOBIN study. The
expression of CPPED1 mRNA in wAT correlated strongly with the mRNA expression
levels of inflammatory genes, including IL1Ra, TNF, IL1,  and  inhibitors  of  the  NF-B
pathway, i.e. IKB, IKB and IKK, when adjusted for baseline body weight. In addition,
there was a positive correlation between the mRNA expression of CPPED1 and IKB in
PBMCs (Table 7). Furthermore, the change of CPPED1 mRNA expression correlated
significantly with the changes in expression of TNF and IL1 (r=0.664, p<0.001; r=0.778,
p<0.001) in wAT and with the expression change of IKB (r=0.428, p=0.016) in PBMCs.
Moreover, CPPED1 mRNA  expression  was  positively  correlated  with  the  mRNA
expression levels of adiponectin receptor 1 (ADIPOR1) at baseline (Table 7), and the
change in CPPED1 mRNA  expression  in  wAT  correlated  strongly  with  the  change  of
ADIPOR1 expression in wAT (r=0.779, p<0.001). There were no significant correlations
between CPPED1 expression and anthropometric or biochemical measures (data not
shown).
Table 7. Partial correlations of CPPED1 mRNA expression in subcutaneous wAT and PBMCs of
the GENOBIN study with selected genes expressed in subcutaneous wAT and PBMCs at
baseline of the intervention in the combined weight reduction and control groups.
Groups combined
(n=46), 0 months
Groups combined
(n=34), 0 months
wAT PBMC
ra p ra p
Gene expression (AU)
PPAR -0.358### 0.020 -
LEP -0.093### 0.559 -
ADIPOQ -0.228
### 0.146 -
ADIPOR1 0.775### <0.001 -0.090+++++ 0.626
ADIPOR2 -0.020### 0.901 -0.033 0.857
IL1Ra 0.364### 0.018 -0.061++ 0.759
TNF 0.695
### <0.001 -0.178++ 0.364
IL1 0.699## <0.001 -0.047++ 0.813
IL-6 0.117### 0.462 -0.069++ 0.726
IKB 0.331# 0.037 0.385+++++ 0.030
IKB 0.431
# 0.005 0.299+++++ 0.096
IKK 0.428# 0.006 -0.293++ 0.130
CPT1B 0.348### 0.024 -
Values are logarithmized, when appropriate. wAT = white adipose tissue; PBMC = peripheral blood
mononuclear cell; a  adjusted for body weight (kg); AU = arbitrary unit; # n = 41; ## n = 42; ### n = 43;
++ n  =  29; +++++ n  =  33;  PPAR =  Peroxisome  proliferator-activated  receptor  gamma;  LEP  =  leptin;
ADIPOQ = adiponectin; ADIPOR = adiponectin receptor; IL1Ra  = interleukin 1 receptor antagonist; TNF
= tumor necrosis factor alpha; IL1 = interleukin 1 beta; IL-6 = interleukin 6;  IKB = nuclear factor of
kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; IKB = nuclear factor of kappa light
polypeptide gene enhancer in B-cells inhibitor, beta; IKK = inhibitor of B kinase-; CPT1 = Carnitine
palmitoyltransferase 1 beta; - not tested; bolded font indicates a statistically significant correlation
(p<0.05)
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5.2 EXPERIMENTS IN WHITE ADIPOSE TISSUE AND ADIPOCYTE CELL CULTURE
5.2.1 Protein expression in human wAT (study II and unpublished, complementary
data) and in preadipocytes and adipocytes (unpublished, complementary data)
To examine the localization of protein expression in formalin-fixed paraffin-embedded
sections of human subcutaneous wAT and in cultured preadipocytes and adipocytes, the
wAT sections (Figure 5) and cells (Figure 6) were stained with an antibody against target
proteins MFAP5 (study II) or CPPED1 (unpublished, complementary data).
As  shown  in  figure  5(B-C),  MFAP5  protein  was  expressed  in  the  interstitial  space,
connective  tissue  (Figure  5B)  and  blood  vessel  walls  (Figure  5C)  of  human  wAT,
indicating that MFAP5 is expressed in the ECM of human wAT. Type I collagen (COL1A),
which was used as  a  positive  control  for  ECM staining,  showed a  similar  localization as
MFAP5 and was expressed in the connective tissue (Figure 5A). Immunohistochemistry of
human  subcutaneous  wAT  sections  also  showed  staining  of  CPPED1  protein  in  the
cytoplasm of adipocytes (Figure 5D).
Figure 5. Protein expression of (A) COL1A (1:10 dilution),-(B-C) MFAP5 (1:10 and 1:500
dilutions)  and  (D)  CPPED1  (1:10  dilution)  in  human  subcutaneous  wAT  sections  by
immunohistochemistry (brownish color: positive staining of target protein, indicated with
arrows; magnification is indicated in figures). Representative figures from 3 independent
stainings.
Immunofluorescence of preadipocytes and differentiating adipocytes showed a
cytoplasmic localization of the CPPED1 protein expression (Figure 6A-B), respectively.
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Figure 6. An immunofluorescence staining of CPPED1 protein in cultured (A) preadipocytes and
(B)  differentiating  adipocytes.  Blue  (1:2000  nuclear  stain,  Hoechst  33258,  red  (1:10  anti-
CPPED1).
5.2.2 Gene expression in SVF/mature adipocytes, and during preadipocyte
differentiation (study II and unpublished, complementary data)
Gene expressions of MFAP5 and CPPED1 were  higher  in  SVF  cells  than  in  mature
adipocytes isolated from human subcutaneous wAT samples (37%, p<0.01; 81%, p<0.01),
respectively (Figure 7A-B). Target gene expression was determined during differentiation
of  SGBS  cells.  The  expression  of MFAP5 was maximal in preadipocytes, and decreased
during differentiation of preadipocytes (Figure 7C), while the expression of CPPED1
mRNA did not change during preadipocyte differentiation (Figure 7D). The expression of
PPAR2, which was used as a marker gene for preadipocyte differentation, increased
constantly during the adipocyte differentiation process, as expected (Figure 7E). In
addition, the differentiation was also confirmed with increased staining of lipid droplets
during  differentiation  by  Oil  Red  O  staining  (Figure  7F)  which  was  performed  to  detect
mature adipocytes.
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Figure 7. The expression of (A) MFAP5 and (B) CPPED1 in stromal-vascular fraction (SVF) cells
(black bar) and in mature adipocytes (white bar). The graph shows the means ±SEM from two
independent experiments, and the values are expressed as relative gene expression levels
normalized to endogenous control PPIA.  **  p<0.01  (mature  adipocytes  vs.  SVF  cells).  The
expression of (C) MFAP5, (D) CPPED1 and  (E) PPAR2 in cultured SGBS cells during
preadipocyte differentiation. The SGBS cells were induced to differentiate and were harvested
in  different  time  points  during  adipocyte  differentiation.  Statistical  significance  was  tested
using one-way ANOVA with Bonferroni’s multiple comparison test. The graph shows the means
±SEM  from  four  independent  experiments,  and  the  values  are  expressed  as  relative  gene
expression levels normalized to endogenous control PPIA. * p<0.05, ** p<0.01, *** p<0.001
(indicated time point versus Day (D)0).(F) Oil-Red-O staining during adipocyte differentiation
(10x magnification)
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5.2.3 Knock-down experiments (studies II and III)
Based on the correlation results, we wanted to better understand the role of the target
genes, MFAP5 and CPPED1, in adipocyte metabolism. Therefore, the effect of target gene
knock-down  by  siRNA  in  SGBS  adipocytes  on  the  expression  of  genes  involved  in
adipogenesis, glucose metabolism, inflammation and the ECM was studied.
5.2.3.1 MFAP5 in adipocyte function (study II)
The knock-down of MFAP5 expression by siRNA induced a significant down-regulation of
MFAP5 protein expression (Figure 8A). At the mRNA level, MFAP5 knock-down
decreased  the  expression  of  several  genes  related  to  ECM  function  and  inflammation
(Figure 8B). However, no significant effects were observed on the expression levels of
genes involved in adipogenesis, like PPAR,  leptin  and  adiponectin  or  in  glucose
metabolism, like GLUT1 and GLUT4 (Figure 8B). Furthermore, MFAP5 knock-down did
not affect insulin-stimulated glucose uptake in SGBS adipocytes (data not shown). In study
I,  we  found  correlations  between  the  expressions  of MFAP5 and ADAM12 and factors
related to inflammation in human AT samples. Therefore, we wanted to examine whether
MFAP5 could modulate the expression of these genes in SGBS adipocytes. The MFAP5
knock-down decreased protein expression of ADAM12 (Figure 8C). MFAP5 knock-down
decreased protein expression of TGF1 and IL-6 (Figure 8D-E) which are known to be
involved in ECM remodeling.
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Figure 8. The effect of MFAP5 knock-down (A) on the mRNA and protein expression of MFAP5,
(B)  on  the  mRNA  expression  of  selected  genes  involved  in  adipocyte  metabolism,  ECM  and
inflammation, on the protein expressions of (C) ADAM12, (D) TGF1 and (E) IL-6. The graph
shows the means ±SEM from three independent experiments, and the values are expressed as
relative gene expression levels normalized to reference gene PPIA for mRNA experiments and
GAPDH for protein experiments. * p<0.05, ** p<0.01 (MFAP5 siRNA/scrambled)
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5.2.3.2 CPPED1 in adipocyte function (study III)
Knock-down of CPPED1 expression decreased the protein expression of CPPED1 time-
dependently (Figure 9A). Moreover, the CPPED1 knock-down  for  48h  increased  mRNA
expression of ADIPOQ, ADIPOR1 and GLUT4, and decreased mRNA expression of
GLUT1 and leptin (Figure 9B).
CPPED1 knock-down modified the expression of genes related to glucose metabolism
suggesting an impact of CPPED1 in adipocyte metabolism. Therefore, we examined
insulin-stimulated glucose uptake in cells treated with or without CPPED1 siRNA. As
expected, insulin-stimulated glucose uptake increased in control cells (Figure 9C).
Interestingly, CPPED1 knock-down increased insulin-stimulated glucose uptake (p<0.05)
compared to insulin-treated control cells. In CPPED1 siRNA transfected cells, Wortmannin
treatment reduced insulin-stimulated glucose uptake (p<0.01) compared to the insulin-
treated cells, suggesting that the CPPED1 siRNA induced effect on insulin-stimulated
glucose uptake could be mediated through a PI3K-dependent pathway (Figure 9C).
The protein expression of ADIPOQ increased time-dependently (Figure 9D), leading to
a significant increase in ADIPOQ protein at 96h after CPPED1 siRNA treatment (p<0.05).
Furthermore, the reduction of CPPED1 expression for 48h tended to increase HMW
adiponectin secretion (p=0.057) into the conditioned medium (Figure 9E). Finally, there
was a tendency (p=0.0686, p=0.1663, p=0.1051, respectively) for time-dependent up-
regulation of GLUT4 protein in response to CPPED1 knock-down (Figure 9F).
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Figure 9. (A) Time-course effect of CPPED1 knock-down on the protein expression of CPPED1.
(B)  The  effect  of CPPED1 knock-down on the mRNA expressions of selected genes. (C) The
effect of CPPED1 knock-down  for  48h  on  insulin-stimulated  glucose  uptake  (the  values  are
expressed  as  counts  per  minute  (CPM)  normalized  to  the  protein  amount  (mg)  of
corresponding well). Statistical significance was tested using one-way ANOVA with Bonferroni’s
multiple  comparison  test.  (D)  Time-course  effect  of CPPED1 knock-down on the protein
expression of ADIPOQ. (E) The effect of CPPED1 knock-down for 48 h on the secretion of HMW
adiponectin into the conditioned medium. (F) Time-course effect of CPPED1 knock-down on the
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protein  expression  of  GLUT4.  The  values  for  the  mRNA  and  protein  expression  results  of
CPPED1 knock-down  are  normalized  to PPIA and  GAPDH,  respectively;  and  statistical
significance was tested using independent samples t-test. The graph shows the means ±SEM
and/or representative figures within time of siRNA exposure from at least three independent
experiments.* p<0.05, ** p<0.01, *** p<0.001; sc: scrambled
5.2.4 Cytokine treatments (study II and unpublished, complementary data)
In study II, we investigated the effect of inflammatory factors on the expression of MFAP5
in SGBS preadipocytes. Incubation of preadipocytes for 48h showed that the lowest
concentration (0.1 ng/mL) of TNF- and IL-6 (Figure 10A,D, respectively) increased the
mRNA expression of MFAP5 (p<0.01, p<0.05, respectively). The highest concentration (10
ng/mL) of TGF1 up-regulated MFAP5 mRNA expression (p<0.05) (Figure 10C). In
contrast, increasing concentrations of IL1 decreased the mRNA expression of MFAP5
(Figure 10B).
Figure 10. The  effect  of  (A)  TNF-,  (B)  IL1,  (C)  TGF1  or  (D)  IL-6  treatment  at  different
concentrations (0.1–10.0 ng/mL) for 48 h on the mRNA expression of MFAP5 in preadipocytes.
The graph shows the means ±SEM from three independent experiments,  and the values are
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expressed as relative gene expression levels normalized to reference gene PPIA. * p<0.05, **
p<0.01, *** p<0.001 compared with control
Our results showed that treatments with TNF and IL1 (10 ng/mL) for 24 h induced IR in
differentiated adipocytes as measured by glucose uptake, with a significant reduction in
insulin-stimulated glucose uptake (Figure 11A). As  shown  in  figure  11B,  treatment  of
preadipocytes with 1.0 and 10.0 ng/mL of TNF- for 24h up-regulated the CPPED1 mRNA
expression. Treatment of mature adipocytes with TNF- tended to increase the CPPED1
mRNA expression, but the results were not significant (Figure 11C).
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Figure 11. The effect of cytokine treatment on (A) glucose uptake (the values are expressed as
counts per minute (CPM) normalized to the protein amount (mg) of corresponding well), and
expression of CPPED1 (B) in preadipocytes and (C) in mature adipocytes.  (The graph shows
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the means ±SEM from three independent experiments, and the values are expressed as
relative gene expression levels normalized to the reference gene PPIA. * p<0.05, ** p<0.01,
*** p<0.001 compared with control)
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6 Discussion
6.1 METHODOLOGICAL CONSIDERATIONS
6.1.1 Subjects
In this study, subjects were carefully selected and well characterized and thus formed a
homogenous study population (119). The study subjects in GENOBIN were overweight or
obese with impaired glucose tolerance or impaired fasting glucose and additionally had
two  other  features  of  the  metabolic  syndrome  and  thus  were  at  high  risk  of  developing
type 2 diabetes and cardiovascular diseases (120). The subjects in the KOBS also had
abnormal glucose metabolism, but they were morbidly obese.
6.1.2 Adipose tissue biopsy techniques
Microarray  has  shown  to  be  an  efficient  tool  to  investigate  simultaneously  thousands  of
genes in a single experiment thus enabling to investigate new players of wAT in human
obesity (121). The development of obesity surgery programs has increased the accessibility
of wAT samples for gene expression experiments. However, the biopsy technique using a
surgical incision was more laborious than the needle biopsy method, which is easier to
obtain and repeat in the same subject, better enabling measurement of the individual
response to an intervention (122). There is evidence showing that although the needle
biopsy method is a rapid and easy technique to obtain wAT samples, it may result in
underrepresentation of SVF of wAT because the components of ECM that reside in SVF
are poorly aspirated by this technique (122). Therefore, it would be preferable to use wAT
samples obtained with the surgical biopsy method when investigating the biology of SVF
in wAT. Good practice would be to replicate the findings of MFAP5 in other studies, like
KOBS, in which surgical biopsy technique was used.
   A drawback is that we used two different wAT biopsy sampling methods to obtain the
wAT samples. It has been demonstrated that gene expression profile could differ between
wAT samples obtained with needle or open biopsy methods (122) and thus the results
need to be interpreted with caution.  Moreover, a limitation in studies I and II was that we
measured mRNA levels and lack the protein samples due to the limited sample size in
needle-biopsy technique used for wAT samples in the GENOBIN study.
   In studies I-III, the gene expression analyses were investigated in subcutaneous wAT
samples and cells isolated from subcutaneous wAT. There is easy accessibility of human
subcutaneous wAT of  the  abdomen,  for  which reason it  is  routinely  used in  both in vivo
and in vitro studies (51). Both white adipose depots, visceral and subcutaneous, have been
shown to be associated with obesity-related complications like IR, type 2 diabetes and
cardiovascular disease (18,123). However, subcutaneous and visceral fat have been
demonstrated to be metabolically different, resulting in differences in their gene
expression patterns (124). In addition, visceral wAT has a unique inflammatory pattern
compared to subcutaneous wAT (123). Visceral fat is usually obtained during surgical
operations from morbidly obese subjects. Therefore, in study I these samples were not
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considered, however, we have gene expression data in visceral wAT related to study III
(unpublished, complementary data).
6.1.3 Statistical issues
A limitation in the GENOBIN study was the small sample size. Statistical power is limited
when carrying out statistical analyses in small groups. However, despite having small
groups we were able to find significant correlations. Different methods were used for wAT
biopsies  and  for  normalization  of  RT-qPCR  data  in  the  study  on  CPPED1  in  human
samples (study III and unpublished, complementary data), and this may complicate the
comparison of the results between the two studies, GENOBIN and KOBS. We used the
standard  curve  method  for  wAT  samples  of  the  GENOBIN  study  and  2	Ct method for
wAT samples of the KOBS study. It could be argued whether using two different methods
is appropriate, but these two methods have been demonstrated to give equivalent results
(125).
Pearson’s correlation coefficient is widely used in clinical studies to measure a
relationship between two variables (126). In studies I and unpublished, complementary
data related to study III, it was used for quantifying relationships between the expressions
of genes of interest and anthropometric and clinical and selected gene expression data.
However, it should be noted that correlation does not necessarily imply for causation
(127). Therefore, functional studies were performed (study II and III) to investigate the
mechanisms behind the correlations.
A drawback in study II is the lack of statistics due to inadequate sample size in the
experiments concerning isolated SVF and mature adipocytes of wAT. The reason for this is
that there were not enough wAT samples for RNA extraction, and we needed to pool
together samples so that there was enough material for further experiments. In the future,
to resolve this problem the number of biological replicates should be increased to ensure
the adequacy of material.
6.1.4 Gene expression
RT-qPCR is a sensitive and powerful method to quantify gene expression and to validate
the data obtained from microarray analysis (118,128). The data in RT-qPCR is relative, and
normalization is crucial for correcting variations in total RNA amount, reverse-
transcription and amplification efficiency. Several methods can be used to normalize data
using a reference gene (99,129). GAPDH and 18S are most commonly used reference genes
(99). However, the expression of reference genes have shown to differ greatly, as seen e.g.
in GAPDH response to dietary intervention (99) and in the in vitro experiments  of  SGBS
cells during differentiation in this thesis work (data not shown). Moreover, 18S has been
shown to have high expression levels (99), also in our samples, and thus was not suitable
as a reference gene. Because the level of expression were much lower in the target genes,
and normalization to  the  expression of 18S would have blunted the results of the target
genes. We tested also other possible candidate reference genes like beta actin and TATA
box binding protein (TBP), but PPIA was chosen as a reference gene because its expression
was the least affected by our in vitro experiments.  In  human  samples  of  the  GENOBIN
study the optimal reference genes were tested using a TaqMan kit of endogenous controls
from Applied Biosystems.
The 2	Ct method is commonly used for the normalization of RT-qPCR data (99,129), and
it was used for normalization of our in vitro experiments. Another method that is generally
used is relative standard curve which was also used for normalization of RT-qPCR data of
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our human samples in the GENOBIN study with PPIA as a reference gene in wAT
samples and GAPDH in PBMCs. The reason why we changed to using the 2	Ct method is
that there is no need to make standard dilutions, and the possible errors made during
dilutions are eliminated. In addition, this method requires fewer reagents and less space in
the plate compared to standard curve method (125).
6.1.5 Protein expression
In studies II and III, western blot, immunohistochemistry and –fluorescence was used for
quantification  of  protein  levels.  However,  it  is  generally  acknowledged  that  the  mRNA
and protein expression levels do not necessarily correlate with each other (130); and
therefore, immunohistochemistry and –fluorescence, western blot or other protein
methods do not necessarily support the mRNA data obtained from cellular experiments.
The mRNA expression level does not tell whether the mRNA is translated to a functional
protein or not, and the mRNA could be regulated only at the transcriptional level (129).
Immunohistochemistry was used for localization of MFAP5 and CPPED1 in wAT sections
(study II and unpublished, complementary data).
   In intact wAT, adipocytes are round and filled with a large lipid droplet and a thin rim
of cytoplasm between the lipid droplet and plasmamembrane. This causes special
challenges for morphological analyses like immunohistochemistry because the sections
from wAT are scarce, very difficult to prepare and give a limited view of the cell/tissue.
Due to this it could be possible that proteins are unevenly distributed and the cytoplasm is
hard to see (131). To overcome this problem we also used immunofluorescence to detect
the localization of CPPED1 protein expression (unpublished, complementary data).
Immunofluorescence maintains the cell structure and enables localization of the protein at
the time of fixation (132).
6.1.6 SGBS cell strain
Experimental models of obesity are needed for the research of biochemical, physiological
and pathological conditions of human obesity (34). An in vitro model of obesity is needed
and at the moment, there is no human adipocyte cell line available for the obesity research
and thus, murine cell lines have been widely used. However, there is strong evidence
showing that all pathological conditions of human obesity do not occur in animal models
(34), and there are several differences between human and murine models of adipocyte
biology e.g. altered cell growth and adipokine expression.
   Although a murine cell line is a validated model, it would be important to have a human
adipocyte cell line, which would be more clinically relevant for human diseases. Simpson
– Golabi – Behmel syndrome (SGBS) cells are derived from SVF of subcutaneous wAT of
an infant with X-linked congenital overgrowth syndrome (117). The SGBS cells have been
shown to be morphologically, biochemically and functionally similar to primary human
adipocytes, showing e.g. a similar glycerol-3-phosphate dehydrogenase (GPDH) activity
and the expression of genes related to adipocyte differentiation, suggesting that these cells
could be used for investigating adipocyte function and as a model of adipogenesis (133-
135). Furthermore, SGBS cells can be used for investigating adipocyte-specific metabolic
functions like insulin-stimulated glucose uptake, lipogenesis and lipolysis (136). Due to
the fact that the amount of preadipocytes obtained from subcutaneous wAT biopsies is
restricted (134) and that SGBS cells are a human cell strain derived from subcutaneous
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wAT, they are an important model to investigate human obesity and adipocyte function
(135). For these reasons, SGBS cells were chosen for this thesis work (studies II and III and
unpublished, complementary data).
6.1.7 siRNA experiments
RNA  interference  (RNAi)  technique  using  double-stranded  small  interfering  RNA
(siRNA) is a powerful, quick and easy technique to decrease the expression of gene of
interest and to investigate the role of a particular gene in cellular functions (137).
However, adipocytes have been shown to be a difficult cell type for gene knock-down due
to their lipid content (137). Therefore, the optimization of siRNA experiments is important
for  achieving  sufficient  and  specific  silencing  in  healthy  adipocytes  (138).  We  used  a
commercial pool of four siRNA oligonucleotides in studies II and III to minimize the off-
target effects and to yield >70% reduction in target gene, and a nonspecific siRNA
oligonucleotide as a negative control.
6.2 GENERAL DISCUSSION
6.2.1 Studies on MFAP5
The effect of weight reduction on gene expression of MFAP5
ECM-associated genes and cytoskeleton components have been shown to be up-regulated
by a high-fat diet and correlated with body weight in mice (41,139). However, not only
weight gain, but also weight loss induces ECM remodeling and modifies the expression of
ECM molecules (140). The role of the ECM during weight reduction or in negative energy
balance is unknown. However, it could be suggested that the synthesis of ECM molecules
is reduced through transcriptional regulation (98).
Kolehmainen et al. (20) have previously shown using Affymetrix microarrays that the
expression of MFAP5 was  down-regulated in  wAT after  weight  reduction in  individuals
with features of the metabolic syndrome. In study I, we confirmed the microarray data and
showed that the expression of MFAP5 mRNA  in  wAT  was  decreased  after  weight  loss,
thus supporting it as a putative molecule involved in wAT biology.
Expression patterns of MFAP5
ECM  proteins  are  predominantly  expressed  in  SVF  of  wAT  (52).  In  line  with  this,  our
results showed that MFAP5 was expressed in ECM of subcutaneous wAT sections and the
expression of MFAP5 was  higher  in  SVF than in  mature  adipocytes,  but  there  was not  a
formal statistical analysis to support this finding due to the small sample size (study II). In
addition, MFAP5 expression was down-regulated during adipocyte differentiation (study
II) similarly to another component of the ECM, fibronectin which together with other ECM
molecules are strongly associated with adipogenesis in order to accommodate wAT
growth (9,15,41,141). Taken together, our results show that preadipocytes and SVF cells
are important source of the MFAP5 expression, and that MFAP5 may be a relevant marker
particularly for the biology of SVF cells.
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MFAP5, adipokines and factors involved in ECM remodeling in wAT
In study I, the associations between the mRNA levels of MFAP5 and bio-clinical and
selected gene expression data were investigated. We showed that MFAP5 expression was
correlated  with  BMI,  the  change  of  body  fat  mass,  and  fasting  concentrations  of
adiponectin, leptin, IL1 and IL1Ra.
   In humans, the level of leptin is directly and adiponectin inversely associated with
obesity and IR (142). In addition, IL1 and IL1Ra are correlated with BMI and
development of IR. Moreover, adiponectin and leptin are involved in obesity-related
angiogenesis and ECM remodeling in other tissues (142,143). Recent studies have
demonstrated that ECM remodeling is important for enlargement of wAT and that
positive correlations exist between the components of ECM in subcutaneous wAT and
BMI (144). Type VI collagen is highly expressed in obese wAT and associated with
increased BMI and inflammation (90). There is also evidence that a loss of collagen VI in
wAT leads to improvements of metabolic profile (14).
   We found correlations between the mRNA expressions of MFAP5 and PPAR2 and
ADAM12 (study I), which  are  both  involved  in  the  development  of  wAT  and  adipocyte
differentiation (87,145,146). Therefore,  we  suggest  that  MFAP5  is  involved  in  ECM
remodeling  in  wAT  and  possibly  wAT  inflammation.  Thus,  MFAP5  may  have  a  role  in
wAT function through modulation of adipokines or factors related to adipogenesis during
development of obesity and reduction of body fat mass in response to weight reduction.
The effect of MFAP5 knock-down
Due to the fact that correlations cannot prove causality, functional studies are necessary to
elucidate the possible mechanisms. Therefore, the role of MFAP5 in adipocyte function
was investigated in an SGBS adipocyte cell culture model.
   In study II, we found that MFAP5 is involved in ECM function and wAT inflammation.
In that study, we demonstrated that reduction in MFAP5 expression decreased the
expression of ECM-related genes, ADAM12 and NOTCH1, and  genes  involved  in  wAT
inflammation, IL1, TGF1 and IL-6. Previous studies have shown that MFAP5 interacts
with NOTCH1 in a cell-dependent manner (107,108). Furthermore, ADAM12 is  shown to
be up-regulated by NOTCH1 activation (147). NOTCH1 is a transmembrane receptor
which determines cell fate, participates in cell-to-cell signaling (148), and notch signaling is
involved in activation of inflammatory processes (149). There is evidence that NOTCH1
contributes  to  tissue  remodeling  in  macrophages  (149),  but  it  is  not  known  whether  a
similar phenomenon could happen also in wAT.
ADAM12 is a cell surface protein involved in cell signaling, cell-ECM interactions and
ECM protein degradation (150,151). In addition, both NOTCH1 and ADAM12 have been
suggested to be involved in the development of wAT, differentiation and adipogenesis
(145,146,148). Furthermore, it has been suggested that ADAM12 is contributes to fibrotic
processes in liver (150), and that MFAP5 is increased in a fibrotic skin disorder associated
with increased deposition of collagen type I (106). Therefore, we suggest that MFAP5 is
associated with remodeling of ECM in wAT, and possibly development of fibrosis,
through the NOTCH1 signaling pathway, involving also ADAM12 (152).
Interestingly, we found that MFAP5 siRNA treatment decreased the expression levels of
factors related to inflammation (study II), suggesting a possible negative feedback loop in
the expression of inflammatory genes. TGF1 is regulated by ECM, e.g. microfibrillar ECM
proteins (153). Furthermore, there is evidence that MFAP5 could mediate its effects
through v3 integrin (105,106) which regulates NF-B activation (154). Therefore,
reduction in the MFAP5 expression might decrease the inflammatory status in wAT. Even
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though the effects were statistically significant, it should be noted that they were modest,
and thus may not be reflected at the physiological level.
The effect of cytokine treatments on the expression of MFAP5
At  the  cellular  level,  IR  in  adipocytes  is  a  characteristic  feature  of  type  2  diabetes.  IR  is
induced by TNF, IL1 and IL-6 in experimental model systems in vitro, in e.g. adipocytes
(30,45,60,155). Therefore, in our experiments TNF, IL1, IL-6 and TGF1 were chosen to
illustrate the chronic low-grade inflammatory state present in obese wAT. Our results
showed that treatments with TNF and IL1 abolished the effect of insulin to take up
glucose in adipocytes, a hallmark of insulin resistance (unpublished, complementary
data).
Interestingly, preadipocytes treated with inflammatory factors TGF1, IL-6 or the
lowest concentration of TNF increased the MFAP5 mRNA  expression  (study II). It has
previously been shown that preadipocytes are able to increase the synthesis of ECM
molecules in an inflammatory environment (52). In addition, inflammatory factors induce
IR through activation of NF-B pathway (78,156), which is also needed for deposition and
remodeling  of  ECM  proteins  and  proliferation  of  preadipocytes  in  response  to
inflammation (15).
TGF1 is a strong pro-fibrotic factor, a modulator of ECM synthesis and a candidate for
adipocyte proliferation (93). Prolonged TGF1 stimulation has been shown to promote
excessive  ECM  deposition  and  may  contribute  to  the  development  of  fibrosis  in  wAT
(9,14,157). Furthermore, TGF has been demonstrated to increase MFAP5 production in
murine fibroblasts (106).
It has also been shown that low levels of TNF- stimulates proliferation of SVF cells of
wAT and fibroblast cell lines (158). This suggests that MFAP5 may be involved in the
deposition of ECM in response to inflammatory factors, and this could be mediated
through  NF-B.  Even  though  we  did  not  measure  proliferation  as  such,  it  could  be
possible that MFAP5 may be related to proliferation of SVF or preadipocytes in response
to inflammatory factors.
On the other hand, treatment of preadipocytes with IL1 decreased the expression of
MFAP5.  The  expression  of  ECM  proteins  have  been  shown  to  be  modified  by  IL1 (88)
possibly involving matrix metalloproteinases (MMPs) that degrade ECM proteins
(159,160). Therefore, the discordance in MFAP5 expression in response to different
cytokines  could  be  due  to  effects  of  MMPs  or  the  activation  of  different  signaling
pathways  in  response  to  cytokines.  At  present,  the  role  of  MMPs  or  the  involvement  of
NF-B in the regulation of MFAP5 expression remains to be defined.
6.2.2 Studies on CPPED1
The effect of weight reduction on the gene expression of CPPED1
We continued to study the role of CPPED1 in wAT (study III and unpublished,
complementary data) and PBMCs (unpublished, complementary data). We showed that in
addition to wAT, the expression of CPPED1 was also decreased in PBMCs after weight
loss  in  the  GENOBIN  and  KOBS  studies.  This  is  in  line  with  a  previous  finding
demonstrating that CPPED1 is expressed in PBMCs (110). Moreover, we found that
CPPED1 expression was higher in subcutaneous wAT than in wAT (+31.2%, p<0.0001) at
baseline in the KOBS (unpublished, complementary data). There is evidence showing that
gene expression pattern could differ between these two wAT depots (124,161), suggesting
that  CPPED1  may  be  more  relevant  for  the  biology  of  subcutaneous  wAT  than  visceral
wAT.
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The reason why CPPED1 expression was not significantly reduced after weight loss in
the  KOBS  study  could  be  in  part  explained  by  differences  in  the  study  designs,  e.g.  the
mechanism of  weight  reduction,  the  amount  of  fat  mass  lost  and the  duration of  follow-
up. The individuals in the KOBS study were morbidly obese (BMI 45 kg/m2), underwent
bariatric surgery and lost 24% of their original weight. In the GENOBIN study participants
were less obese (BMI 32.9 kg/m2), and their weight reduction was modest (~5%).
Moreover, the differences in study design may have different effects on possible
compensatory mechanisms. A further reason could be the use of two different wAT biopsy
methods, which affects the gene expression patterns in wAT (122).
CPPED1 and factors involved in AT inflammation
Our results showed that CPPED1 expression correlated with the expression of genes
related to inflammation, such as TNF, IL1, IL1Ra, and inhibitors of NF-B pathway
(IKB, IKB, IKK) in wAT, indicating that CPPED1 could be involved in wAT
inflammation. In addition, our results suggest that CPPED1 may contribute to the
development of IR in response to TNF and IL1 treatments at the cellular level
(unpublished, complementary data).
In obesity, the production and expression of many inflammatory cytokines, like TNF
and IL1, is increased (7,8,60). The effects of these cytokines are mainly mediated through
activation of IKK/NF-B pathway (78,156) along with increasing adiposity, and recent
studies  have  highlighted  the  role  of  IKK and  NF-B  and  its  target  genes  in  the
development of IR and type 2 diabetes (78).
The expression of IL1Ra is increased in obesity and has been suggested to be associated
with the development of IR (60). Conversely, reduction in the IL1Ra expression  in
response to weight loss has been suggested to reflect improvements in insulin and glucose
metabolism (162,163).
Moreover, immune cells and macrophage infiltration into wAT may have a central role
in the development of IR in adipocytes (60), since it has been shown that factors secreted
by macrophages are capable of impairing insulin sensitivity, e.g. through increased
lipolysis (44). Thus, monocytes, which are a cell type in PBMCs and differentiate into
macrophages in wAT, could be used as a model to study inflammation and its association
with IR (45).
Based on correlation results in humans and in vitro experiments with inflammatory
factors, CPPED1 may be associated with the development of IR in wAT. Further
investigations are necessary, however, to determine which mechanisms might be involved
in the regulation of the CPPED1 expression in adipocytes in response to inflammation.
Expression pattern of CPPED1
CPPED1 protein was expressed in wAT sections, and there was a higher expression of
CPPED1 in SVF than in mature adipocytes (unpublished, complementary data). Moreover,
the expression pattern of CPPED1 was not changed during adipocyte differentiation (study
III). We also showed cytoplasmic expression of CPPED1 protein in preadipocytes and
adipocytes (unpublished, complementary data).
WAT is a heterogeneous pool of different types of cells like adipocytes and SVF cells,
including preadipocytes, endothelial cells and several immune cells (164). It has been
shown that adipocytes and immune cells are in close proximity in wAT (12,156).
Therefore, it  could be suggested that both cellular fractions of wAT, adipocytes and SVF
cells,  are contributing to CPPED1 expression in wAT. The present results showed that at
least preadipocytes and adipocytes are involved in the expression of CPPED1. However,
specific cell types could not be distinguished, and further experiments are needed.
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The effect of CPPED1 knock-down
The possible effect of CPPED1 knock-down in insulin sensitivity and glucose metabolism
was examined by measuring insulin-stimulated glucose uptake in mature adipocytes. The
down-regulation of CPPED1 mRNA as such enhanced insulin-stimulated glucose uptake,
which was inhibited by treatment with wortmannin, a PI3K-specific inhibitor. Therefore,
the CPPED1 knock-down induced improvement in glucose uptake may be mediated
through a PI3K/Akt-dependent pathway.
The knock-down of CPPED1 expression in mature adipocytes increased the gene and
protein  expression  of  ADIPOQ.  There  was  also  a  trend  for  enhanced  secretion  of  HMW
adiponectin into the conditioned medium indicating that CPPED1 may regulate
adiponectin signaling in wAT. Furthermore, gene expression levels of ADIPOR1 and
GLUT4 were also increased, and there was a tendency for increased GLUT4 protein
expression  due  to CPPED1 knock-down. The expression of CPT1B mRNA  was  also
increased in response to CPPED1 knock-down. In human data from the present study
(unpublished, complementary data), there was a clear correlation between expression of
CPPED1 and ADIPOR1 and CPT1B.
The effects of adiponectin are mediated through adiponectin receptors 1 and 2 (13,59).
Adiponectin has been shown to be directly involved in enhancing insulin sensitivity
through phosphorylation of the insulin receptor and GLUT4 translocation. Adiponectin
also indirectly improves insulin sensitivity via 5’-AMP-activated protein kinase (AMPK)
activation, which leads to decreased malonyl-coenzyme A production and increased CPT1
activity, fatty acid oxidation and reduction in FFA levels in the liver and skeletal muscle
(3,57,68,165). Furthermore, the expression of adiponectin receptors is down-regulated in
obesity (13). However, there is some controversy because previously it has been shown
that the expression of ADIPOR1 may be increased in skeletal muscle in obese subjects (3).
This could be because higher expression level of adiponectin receptors may compensate
for the decreased levels of circulating adiponectin seen in obesity and IR (3).
The main tissue for insulin-stimulated glucose uptake is skeletal muscle (166). In
addition, there is evidence showing that reduction in GLUT4 expression  and  glucose
uptake can induce IR in AT (166). The role of the GLUT4 transporter in insulin-stimulated
glucose uptake has also been shown to be important for glucose homeostasis in AT (72).
As shown in mice, GLUT4 over-expression has increased insulin sensitivity. Moreover,
GLUT4 knock-out from fat tissue has induced IR, as seen in muscle-specific GLUT4 knock-
out (72). However, insulin-stimulated glucose uptake induces the GLUT4 translocation to
the plasma membrane rather than up-regulating GLUT4 intrinsic activity in adipocytes
(75,167). On the other hand, the expression of GLUT4 is reduced in adipocytes, but not in
muscle. This suggests that the regulation of GLUT4 expression in adipocytes could be
important in the development of obesity, although the role of decreased GLUT4 expression
in the development of IR is not completely understood (166,168). Overall, insulin-
stimulated glucose uptake in wAT has an important role for glucose homeostasis, and the
obesity-induced reduction in GLUT4 expression is involved in the development of IR and
subsequently type 2 diabetes (166).
Furthermore, the present results showed that the CPPED1 knock-down decreased the
mRNA  expression  of  leptin  (study III). There is evidence that leptin is involved in
enhancing insulin sensitivity by inducing fatty acid oxidation and decreasing ectopic fat
accumulation in non-adipose tissues through AMPK activation (71). This suggests that
also leptin may be involved in CPPED1-induced effects on insulin action via indirect
actions on glucose uptake.
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Taken together, these results suggest improved glucose metabolism in response to
CPPED1 reduction,  which may be  a  result  from the  concomitant  increase  in  adiponectin
levels and activation of its signaling pathway either directly or indirectly (Figure 12).
6.3 FUTURE IMPLICATIONS
Current publications about MFAP5 demonstrate its role in elastinogenesis, cell survival
and angiogenesis. The results presented in this thesis provide novel information about the
roles  of  MFAP5 and CPPED1 in  wAT and adipocyte  function,  which,  to  our  knowledge,
has never been studied before.
The production of various cytokines and adipokines is altered in obesity, and the
function of these adipokines and adipocytokines is important for cross-talk with other
organs. There is a complex interaction between cytokines and ECM, which is essential in
maintaining tissue homeostasis and regulating ECM deposition (4,158,169). We could not
show a clear dose-response effect of the cytokines examined suggesting that treatment
may not have a direct effect on the expression of target genes. If the observed changes on
the MFAP5 and CPPED1 expression also occur in vivo, different cytokines, separately or in
combination, may influence the their properties in wAT. Further studies are necessary to
unravel whether MFAP5 is involved in ECM remodeling, and whether MFAP5 expression
is regulated by MMPs. In addition, the role of MFAP5 in proliferation of preadipocytes in
response to inflammation needs to be examined.
Since  macrophages  and  adipocytes  are  in  close  proximity  in  wAT,  and CPPED1 was
found to be expressed in wAT, PBMCs and adipocytes, a macrophage-adipocyte co-
culture system could provide novel information about the intercellular cross-talk and shed
light on the relationship between CPPED1 and inflammation. Furthermore, it would be
interesting to investigate the role of CPPED1 in macrophages.
More mechanistic studies are needed to investigate the role of CPPED1 in the
phosphorylation status of insulin signaling molecules, such as IRS and other downstream
targets in order to find specific effects at the molecular level. Moreover, the interaction
between CPPED1 and adiponectin needs to be investigated in more detail. It would be also
interesting to examine whether over-expression of CPPED1 could induce IR at the cellular
level.
6.4 CONCLUSIONS
The possible processes involved in the regulation of MFAP5 and CPPED1 expression in
wAT and adipocytes are illustrated in figure 12. Obesity leads to increased low-grade
inflammation  and  ECM  remodeling,  both  of  which  are  reduced  after  weight  loss  and
concomitant improved glucose metabolism and insulin sensitivity in wAT. In obese wAT,
inflammation induces ECM overproduction, which may finally lead to the development of
fibrosis.
   The present results show that MFAP5 expression in wAT decreases after weight loss and
correlates  with  factors  related  to  ECM  remodeling  and  wAT  inflammation.  In  addition,
inflammatory factors up-regulate the expression of MFAP5 in preadipocytes. These
findings suggest that obesity-related inflammation either directly or indirectly increases
MFAP5 expression in wAT through effects on ECM. Furthermore, the down-regulated
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MFAP5 expression  further  decreases  the  expression  of  ECM  components  involved  in
adipogenesis and ECM remodeling, and decreases inflammatory status in adipocytes. In
this way, down-regulation of MFAP5 expression possibly forms a negative feedback loop
and thereby may reduce the obesity-induced inflammation and ECM remodeling in wAT.
These results suggest that MFAP5 is associated with wAT inflammation and ECM
function.
The present results hypothesize that increased wAT inflammation is responsible for the
up-regulated CPPED1 expression, possibly through activation of IKK/NF-B, leading to
impaired insulin signaling and development of IR. The improvement in glucose uptake
after  weight  loss  could  be  partly  due  to  the  decreased  expression  of CPPED1 through  a
PI3K-dependent pathway, and possibly adiponectin signaling could either directly or
indirectly play a role in this regulation. This work demonstrates that MFAP5 and CPPED1
have a role in wAT biology and could contribute to complications in dysfunctional wAT.
The studies presented in this thesis work demonstrate that moderate weight reduction
down-regulated the expression of MFAP5 and CPPED1 in human subcutaneous wAT and
PBMC samples. The health benefits of moderate weight reduction may originate from
reduced overall adiposity and inflammation and modulated production of adipokines and
ECM proteins. Furthermore, down-regulated expression of the target genes in vitro
showed beneficial effects on adipocyte metabolism, but whether it could be reflected also
in vivo needs to be investigated.
Taken together, the results provide novel insights about the function of MFAP5 in ECM
remodeling  and  wAT  inflammation  and  the  role  of CPPED1 in glucose metabolism,
possibly  via  adiponectin-mediated  mechanisms,  which  are  important  processes  in  the
development of obesity- related morbidities, like IR, type 2 diabetes and cardiovascular
diseases. Finally, these results support the strategy to find new putative genes that might
be related to obesity-related wAT dysfunction. Along with this line, we have identified
genes whose expression levels are modified with weight change and which are involved
in processes relevant for wAT biology, like glucose metabolism, inflammation and ECM
function.
49
Figure 12. Possible roles of MFAP5 and CPPED1 in wAT biology and adipocyte function. Intact
arrows: known effects in wAT samples/cell experiments; Dashed arrows/lines: possible
effects; up-regulation; down-regulation (red arrows: unbeneficial, green arrows: beneficial)
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7 Summary
The most important results and methods of this thesis work are presented in table 8.
Table 8. The key methods and results of this thesis work
Results
Methodology MFAP5 CPPED1
Human samples
The effect of weight
reduction on gene
expression
 in wAT of the GENOBIN
study (study I)
 in wAT and PBMCs of the GENOBIN
study and in PBMCs of the KOBS study
(study III, unpublished, complementary
data)
Correlation analysis in
the GENOBIN study
Correlated with factors
related to ECM remodeling
and wAT inflammation (study
I)
Correlated with the expression of
inflammatory genes in wAT and PBMCs
(unpublished, complementary data)
Immunohistochemistry
of human wAT samples
Protein expressed in ECM and
blood vessels (study II)
Protein expressed in cytoplasm of
adipocytes (unpublished, complementary
data)
Isolation of SVF from
human wAT samples
Gene expression higher in
SVF than in mature
adipocytes (unpublished,
complementary data)
Gene expression higher in SVF compared
to mature adipocytes (unpublished,
complementary data)
SGBS cell culture
Adipocyte
differentiation
Gene expression was down-
regulated during adipocyte
differentiation (study II)
Gene expression was not changed during
adipocyte differentiation (study III)
Immunofluorescence * Protein expression was localized in
cytoplasm of preadipocytes and mature
adipocytes (unpublished, complementary
data)
Cytokine treatment TNF, TGF1 and IL-6
treatments increased MFAP5
gene expression in
preadipocytes (study II)
TNF treatment increased CPPED1 gene
expression in preadipocytes and mature
adipocytes (unpublished, complementary
data)
siRNA treatment  the expression of ECM
components and
inflammatory genes/proteins
(study II)
 the expression of genes/proteins
related glucose metabolism (study III)
Glucose uptake MFAP5 siRNA treatment did
not have an effect on glucose
uptake (study II)
CPPED1 siRNA treatment  insulin-
stimulated glucose uptake (study III)
ELISA * CPPED1 siRNA treatment tended to
increase ADIPOQ secretion (study III)
MFAP5, microfibrillar-associated protein 5; CPPED1, calcineurin-like phosphoesterase domain 1; wAT,
white adipose tissue; PBMCs, peripheral blood mononuclear cells; GENOBIN, gene expression in obesity
and insulin resistance; KOBS, Kuopio obesity surgery; ECM, extracellular matrix; SVF, stromal-vascular
fraction;  TNF, tumour necrosis factor alpha; TGF1, transforming growth factor beta 1; IL-6,
interleukin 6; siRNA, small interfering RNA; ELISA, enzyme-linked immunosorbent assay; * was not
measured;  up-regulation; down-regulation
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This study focused on the roles of 
microfibrillar-associated protein 
5 (MFAP5) and calcineurin-like 
phosphoesterase domain 1 (CPPED1) 
in white adipose tissue (wAT) biology 
and adipocyte function. The results 
demonstrate that MFAP5 and CPPED1 
could contribute to complications in 
dysfunctional wAT. Furthermore, 
the results suggest that MFAP5 is 
involved in extracellular matrix 
function and wAT inflammation. In 
addition, the results provide novel 
insight about the role of CPPED1 in 
glucose metabolism, possibly via 
adiponectin-mediated mechanisms.
